WO2018066956A1 - Composition comprising schisandrae fructus-containing composite extract for preventing or treating blood circulation-related disease - Google Patents
Composition comprising schisandrae fructus-containing composite extract for preventing or treating blood circulation-related disease Download PDFInfo
- Publication number
- WO2018066956A1 WO2018066956A1 PCT/KR2017/011049 KR2017011049W WO2018066956A1 WO 2018066956 A1 WO2018066956 A1 WO 2018066956A1 KR 2017011049 W KR2017011049 W KR 2017011049W WO 2018066956 A1 WO2018066956 A1 WO 2018066956A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- schisandra chinensis
- composition
- blood circulation
- pharmaceutical composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 185
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 70
- 201000010099 disease Diseases 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 230000017531 blood circulation Effects 0.000 title claims abstract description 51
- 239000002131 composite material Substances 0.000 title abstract description 16
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 230000002265 prevention Effects 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000003674 animal food additive Substances 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 12
- 235000013376 functional food Nutrition 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 240000006079 Schisandra chinensis Species 0.000 claims description 122
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 121
- 208000007536 Thrombosis Diseases 0.000 claims description 43
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 20
- 235000003373 curcuma longa Nutrition 0.000 claims description 20
- 235000013976 turmeric Nutrition 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 244000008991 Curcuma longa Species 0.000 claims description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 10
- 206010008118 cerebral infarction Diseases 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 40
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 36
- 230000000694 effects Effects 0.000 description 23
- 229920001525 carrageenan Polymers 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000679 carrageenan Substances 0.000 description 16
- 235000010418 carrageenan Nutrition 0.000 description 16
- 229940113118 carrageenan Drugs 0.000 description 16
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 244000163122 Curcuma domestica Species 0.000 description 7
- 235000008708 Morus alba Nutrition 0.000 description 7
- 240000000249 Morus alba Species 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- -1 specifically Chemical class 0.000 description 7
- 239000008513 turmeric extract Substances 0.000 description 7
- 229940052016 turmeric extract Drugs 0.000 description 7
- 235000020240 turmeric extract Nutrition 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000209504 Poaceae Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 240000002791 Brassica napus Species 0.000 description 2
- 235000011293 Brassica napus Nutrition 0.000 description 2
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000004459 forage Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003173 Arterial rupture Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000958526 Cuon alpinus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 231100000483 muscle toxicity Toxicity 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Definitions
- the present invention is a composition for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient, a method for treating a blood circulation-related disorder comprising administering the composition to an individual in need thereof, Schisandra chinensis It relates to a quasi-drug composition, feed additives and health functional food composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing.
- Hyperlipidemia is a disease caused by increased blood lipids such as cholesterol in blood circulation and blood lipids attached to the artery wall. Chronic inflammatory reactions and narrowing of the arterial wall cause blood vessels to harden. Atherosclerosis is induced, and in the long run, clots generated therefrom block coronary arteries and cerebrovascular vessels, causing myocardial infarction, stroke and cerebral infarction.
- drugs for treating hyperlipidemia are used as statin drugs that have inhibitory activity against HMG-CoA reductase, which plays an important role in the synthesis of cholesterol in the liver. It is known to have side effects such as muscle toxicity.
- hypertension is a condition in which the arterial blood pressure is chronically high, and systolic blood pressure is 140 mmHg or more or diastolic blood pressure is 90 mmHg or more in an adult 18 years or older, and arteriosclerosis is a fat containing cholesterol, phospholipids, and calcium. Plaque accumulates in the vascular lining, causing the arteries to become rigid, losing elasticity, and narrowing. Eventually, the arterial rupture, detachment, etc. occur due to impaired blood supply or increased pressure.
- drugs for inhibiting hypertension drugs for inhibiting angiotensin converting enzyme activity or drugs for inhibiting binding between angiotensin and angiotensin receptors
- various statins which are HMG-CoA reductase inhibitors, are used for the treatment of atherosclerosis.
- statins which are HMG-CoA reductase inhibitors
- the therapeutic agent is also known to have side effects when used for a long time, there is still a need for the development of a more effective therapeutic agent.
- the present inventors have made efforts to develop natural substances that have no side effects and are effective in blood circulation-related diseases including hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke or cerebral infarction, etc.
- the present invention was completed by confirming that Schizandra chinensis-C extract or Schizandra chinensis complex extract inhibited thrombus formation and inhibited platelet aggregation, which is effective in preventing, improving or treating blood circulation-related diseases.
- An object of the present invention to provide a pharmaceutical composition for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- Another object of the present invention is to provide a method for treating a blood circulation related disease, comprising administering the pharmaceutical composition for preventing or treating the blood circulation related disease to an individual in need thereof.
- Another object of the present invention to provide a quasi-drug composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- Another object of the present invention to provide a feed additive for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- Another object of the present invention to provide a health functional food composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- the complex extract containing Schisandra chinensis of the present invention in particular, Schisandra chinensis extract or Schisandra chinensis complex extract can be effectively used for the prevention or treatment of blood circulation-related diseases by inhibiting thrombus formation and effectively inhibiting platelet aggregation.
- the composition can be used as a quasi-drug composition, health functional food composition, or feed additives for the prevention or improvement of blood circulation-related diseases.
- 1 is a graph showing the thrombus formation inhibitory ability of Schizandra chinensis extract of various ratios.
- Figure 2 is a graph showing the thrombus generation inhibitory ability of Schizandra chinensis compound extract of various ratios.
- Figure 3 is a graph showing the antithrombotic activity of Schizandra chinensis, Turmeric alone and Schizandra chimus extract.
- Figure 4 is a graph showing the thrombus formation inhibitory ability of Schizandra chinensis, S. chinensis extract and Schizandra chinensis combined extract.
- Figure 5 is a graph showing the platelet aggregation inhibitory ability of Schizandra chinensis complex extract of various ratios.
- Figure 6 is a graph showing the platelet aggregation inhibitory ability of Schizandra chinensis compound extract of various ratios.
- Figure 7 is a graph comparing the thrombus generation inhibitory ability of the known Schizandra-containing 19 species complex extract and Schizandra complex extract of the present invention.
- Figure 8 is a graph comparing the platelet aggregation inhibitory ability of the known Schizandra-containing 19 species complex extract and Schizandra complex extract of the present invention.
- One aspect of the present invention for achieving the above object is for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis, specifically, Schisandra chinensis complex extract or Schisandra chinensis complex extract as an active ingredient. It provides a pharmaceutical composition.
- the present invention provides a preventive or therapeutic use of blood circulation-related diseases of the composition comprising a complex extract containing Schisandra chinensis, specifically Schisandra chinensis complex extract or Schisandra chinensis extract as an active ingredient.
- Schisandra chinesis in the present invention means a ball-shaped dark red fruit having a diameter of about 1 cm, and contains 1 to 2 red juices and reddish brown seeds. Types include North Schisandra chinensis, South Schisandra chinensis and Black Schisandra chinensis, and it contains ingredients such as cezandrarin, gomisin, citric acid, malic acid and citric acid.It is known to be used as a tonic by strengthening the heart, lowering blood pressure and enhancing immunity. have. Schisandra may be purchased and used commercially, or may be collected or grown in nature, but is not limited thereto.
- curcumae Longae Rhizoma in the present invention, also called ulumum (Tumeric), means a perennial herb of Ginger-necked ginger family, which has been used as a herbal medicine in oriental medicine.
- Turmeric has a spicy and bitter taste, the outside of the rhizome is light yellow, and the inside is scarlet and has a camphor-like scent. It is also known that flowering ear comes out before the leaves, and yellow flowers bloom in the leaf axes in April and June.
- Turmeric may also be purchased and used commercially, or may be one that is collected or cultivated in nature, but is not limited thereto.
- the stem, leaf, or root portion of turmeric may be used, but is not limited thereto.
- mulberry leaf in the present invention refers to the leaves of the mulberry (Morus alba L.), which is a deciduous broad-leaved arboreous tree belonging to the rose family Mulberry family, and in Oriental medicine, it refers to a medicinal herb obtained by drying the leaves of the mulberry tree.
- Mulberry leaves can be harvested annually and contain high amounts of secondary metabolites such as flavonoids and alkaloids.
- the upper leaf may also be purchased and used commercially, or may be used collected or cultivated in nature, but is not limited thereto, and the portion used may use the leaf of the mulberry leaf as the meaning of the upper leaf.
- extract is an extract containing Schisandra chinensis, and may include an extract extracted Schisandra chinensis alone.
- composite extract in the present invention means an extract containing two or more substances, specifically, an extract containing one or more substances other than Schisandra chinensis, more specifically, Schisandra chinensis extract Or Schizandra chinensis compound extract, but is not limited thereto.
- the complex extract is a mixture of Schisandra chinensis and other substances other than Schisandra chinensis extract, and Schicho and Schisandra chinensis extract, respectively, to prepare an extract and then to extract the extract, specifically, turmeric or lettuce in Schisandra chinensis It may include, but is not limited to, an extract obtained by mixing turmeric or upper leaf extract with the extracted extract and Schisandra chinensis extract.
- the extract is a low alcohol of 1 (C1) to 4 (C4) carbon, such as water, methanol, ethanol, etc. in a volume of about 1 to 20 times the dry weight, specifically about 3 to 5 times the dry weight of each component Elution with a polar solvent such as or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, but is not limited thereto,
- the extraction temperature is 20 °C to 100 °C, specifically 60 °C to 100 °C Can be extracted, but is not limited thereto.
- the extraction period may be an extract extracted using an extraction method such as hot water extraction, cold needle extraction, reflux cooling extraction or ultrasonic extraction for about 1 hour to 4 days, but may exhibit a therapeutic effect of the blood circulation-related diseases of the present invention.
- the extract is not limited thereto, and may include all extracts, dilutions or concentrates of the extracts, dried products obtained by drying the extracts, or all of these modifiers or purified products.
- the Schisandra chinensis extract, turmeric extract, upper leaf extract can be extracted from various organs of natural, hybrid, mutant plants, for example, roots, ground, stems, leaves, flowers, trunks of fruits, bark of fruit as well as plant tissue culture Extractable from water.
- the Schisandra chinensis extract and turmeric extract may include Schisandra chinensis extract and turmeric extract in a weight ratio of 0.1 to 10: 1, specifically, but may include 0.5 to 2: 1 by weight, but is not limited thereto.
- the Schisandra chinensis and upper leaf complex extract may include Schisandra chinensis extract and the upper leaf extract in a weight ratio of 0.1 to 10: 1, specifically, may comprise a weight ratio of 0.25 to 1: 1, but is not limited thereto.
- the composition may inhibit thrombus formation, and in particular, may have a platelet aggregation inhibitory ability, and thus may be used for the prevention or treatment of a number of blood circulation-related diseases including thrombosis.
- blood circulation related disease refers to various diseases caused by metabolic problems or caused by blood clots, and the complex extract containing Schisandra chinensis of the present invention can be treated or prevented with an active ingredient.
- Diseases that are present include, but are not limited to, one or more diseases selected from the group consisting of hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke and cerebral infarction.
- hypolipidemia refers to a disease caused by a large amount of fat in the blood due to poor metabolism such as triglycerides and cholesterol, specifically, triglycerides in the blood, LDL cholesterol, phospholipids and free fatty acids, etc.
- the lipid component of the increased state may include high cholesterol or hypertriglyceridemia, but is not limited thereto.
- the term "hypertension” refers to a state in which the arterial blood pressure is chronically high, and the systolic blood pressure is 140 mmHg or more or the diastolic blood pressure is 90 mmHg or more in an adult 18 years or older, and may be caused by obesity or the like.
- the term "arteriosclerosis” is a disease caused by the accumulation of fatty substances (plaque) containing cholesterol, phospholipids, calcium, etc. in the vascular lining, which causes the arteries to become hard, lose elasticity, and narrow, and thus inhibit blood supply or pressure. This means that the artery is ruptured or peeled off.
- plaque fatty substances
- myocardial infarction refers to a disease in which the heart muscle is suddenly blocked due to blood clots, spasms, or the like, and the heart muscle is damaged. It refers to a condition that refers to a condition in which no cause can be found other than a disease of cerebrovascular vessels. Specifically, a disease caused by blockage of the cerebrovascular vessels is called a cerebral infarction or ischemic stroke, and blood flows into the brain tissue due to the rupture of the cerebrovascular vessel. This outflow disease is called cerebral hemorrhage or hemorrhagic stroke.
- the platelet obtained from the blood of the rat is reacted at different ratios of the Schizandra chinensis complex extract or Schizandra chinensis complex extract, and then platelet aggregation is promoted by adding collagen as a platelet aggregation promoter.
- the mixture ratio of Schisandra chinensis was 0.25 to 4: 1
- the Schisandra chinensis mixture ratio of 0.25 to 4: 1 has excellent platelet aggregation inhibitory ability.
- the complex extract containing Schisandra chinensis of the present invention specifically, Schisandra chinensis complex extract or Schisandra chinensis complex extract can be used for the prevention or treatment of diseases related to blood circulation, in particular diseases caused by blood clots.
- prevention refers to any action that inhibits or delays the development of blood circulation-related diseases such as hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke, and cerebral infarction by administration of a composition according to the present invention.
- treatment refers to any action by which administration of a composition according to the present invention improves or advantageously alters the symptoms of the diseases.
- the content of the complex extract containing Schisandra chinensis contained in the pharmaceutical composition according to an embodiment of the present invention is not particularly limited thereto, but is 0.0001 to 50% by weight based on the total weight of the final composition, more specifically 0.01 to It may be included in an amount of 5% by weight.
- compositions of the invention as specific embodiments of the invention are pharmaceutical compositions.
- the composition of the present invention is a pharmaceutical composition
- the composition may include a pharmaceutically acceptable carrier.
- composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
- Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
- lubricants such as magnesium stearate, talc and the like are also used.
- Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- the non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
- the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have one formulation.
- composition of the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is defined as the type and severity, age, sex, Activity, sensitivity to drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
- a typical daily dosage of a composition comprising a complex extract containing Schisandra chinensis according to the invention as an active ingredient may range from 10 to 1,000 mg / kg, preferably 10 to 500 mg / kg, once or It can be administered in several divided doses.
- the prophylactic or therapeutic agent for blood circulation-related diseases such as hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke and cerebral infarction may be administered daily or intermittently, and the number of administrations per day is divided once or twice or three times. It is possible to administer.
- the frequency of administration in the case where the two active ingredients are single drugs may be the same or different times.
- Another aspect of the invention provides a method of treating a blood circulation related disease, comprising administering a complex extract containing Schisandra chinensis to a subject in need thereof.
- the term "individual” refers to all animals including humans who have already developed or may have a blood circulation related disease, and by administering to the subject a composition comprising a complex extract containing Schisandra chinensis as an active ingredient, the disease Can be effectively prevented and treated.
- the subject means an entire mammal including a dog, cow, horse, rabbit, mouse, rat, chicken or human, but the mammal of the present invention is not limited to the above examples.
- the optimal amount and dosage interval of the individual doses of the composition of the present invention will be determined by the nature and extent of the disease being treated, the dosage form, the route and site, and the age and health of the particular patient being treated and ultimately used by the physician. It will be appreciated by those skilled in the art that the appropriate dosage will be determined. Such dosing can be repeated as often as appropriate. If side effects occur, the dosage and frequency can be altered or reduced in accordance with normal clinical practice.
- the route of administration of the composition may be administered via any general route as long as it can reach the desired tissue.
- the composition of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, subcutaneous administration, intradermal administration, oral administration.
- the composition may also be administered by any device in which the active agent may migrate to the target cell.
- Another aspect of the present invention provides a quasi-drug composition comprising the complex composition as an active ingredient.
- composition of the present invention may be added to the quasi-drug composition for the purpose of preventing or improving blood circulation related diseases.
- the term " improvement" refers to an effect of alleviating the symptoms of blood circulation-related diseases such as hyperlipidemia or arteriosclerosis by applying a quasi-drug composition comprising a complex extract containing Schizandra chinensis of the present invention.
- the term "quasi drug” refers to a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Or non-machinery and the like, or any of the agents used for sterilization, insecticide and similar purposes for the purpose of preventing infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases.
- Means the goods used are not instruments, machines or devices, and the items used for the purpose of pharmacologically affecting the structure and function of humans or animals except those which are not devices, machines or devices.
- the quasi-drug may include external skin preparations or personal hygiene products.
- the complex extract containing Schisandra chinensis of the present invention is used as an quasi-drug additive
- the extract may be added as it is or used with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method, and the mixed amount of the active ingredient may be used. It may be appropriately determined depending on the purpose.
- the external preparation for skin is not particularly limited thereto, but may be preferably used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel.
- the personal hygiene products are not particularly limited, but preferably soap, cosmetics, wet wipes, tissue paper, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, make-up, foundation, ball touch, mascara, eye shadow, Sunscreen lotions, hair care products, air freshener gels or cleaning gels.
- another example of the quasi-drug composition of the present invention is a disinfectant cleaner, shower foam, gagreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.
- Another aspect of the present invention provides a feed additive for preventing or improving blood circulation-related diseases, including a complex extract containing Schisandra chinensis as an active ingredient.
- the complex extract containing Schisandra chinensis of the present invention may be added to a feed additive or a feed composition comprising the feed additive for the purpose of preventing or improving blood circulation related diseases.
- the term "feed additive” is a substance added to the feed for the purpose of various effects, such as supplementation of nutrients and weight loss prevention, improving the digestive availability of the fiber in the feed, improving the quality, prevention of reproduction disorders and improving conception, prevention of high temperature stress in summer Means.
- the feed additive of the present invention corresponds to a feed supplement under the Feed Control Act, and includes mineral preparations such as sodium bicarbonate, bentonite, magnesium oxide, and composite minerals, mineral preparations such as trace minerals such as zinc, copper, cobalt, and selenium, and keratin.
- Vitamins such as vitamin E, vitamin A, D, E, nicotinic acid, vitamin B complex, protective amino acids such as methionine, lyric acid, protective fatty acids such as fatty acid calcium salt, probiotics (lactic acid bacteria), yeast culture, mold Probiotics such as fermented products, yeasts and the like may be further included.
- the term "feed” means any natural or artificial diet, one meal, or the like or any ingredient of the one meal for the animal to eat, ingest, and digest.
- the feed comprising the composition for the prevention or treatment of blood circulation-related diseases according to the present invention as an active ingredient can be prepared in various forms of feed known in the art, specifically thick feed, forage and / or special Feed may be included.
- the rich feed includes seed fruits containing grains such as wheat, oats and corn, and by-products obtained by refining grains, bran, beans, fluids, sesame seeds, linseed, coco, etc., including rice bran, bran and barley bran.
- Fish soluble which is a concentrate of fresh liquids obtained from fish residues, fish residues, and fish residues such as by-products such as seaweed, sweet potatoes, and potatoes, which are the remaining components of starch residue. soluble), meat meal, blood meal, milk powder, skim milk powder, milk from cheese, and whey, the balance of manufacturing casein from skim milk, dried foods such as dried whey, yeast, chlorella, and seaweed. This is not restrictive.
- raw vegetables such as grasses, grasses, and green grass, fodder turnips, fodder beets, and root vegetables such as Lutherbearger, a type of turnip, raw grass, green grass crops, and grains Silage (silage), grasses, grasses, and dried hay, straws of breeders, and leaves of legumes, which are filled and fermented by lactic acid fermentation, are not limited thereto.
- Special feeds are supplemented with mineral feeds such as oyster shells and rock salts, urea feeds such as urea and its derivatives, diureide isobutane, and natural feed ingredients.
- Feed additives and dietary supplements which are substances added in small amounts, are not limited thereto.
- Feed composition comprising the composition for the prevention or treatment of blood circulation-related diseases according to the present invention can be prepared by adding a complex extract containing Schisandra chinensis in a suitable effective concentration range according to various feed production methods known in the art.
- Feed composition according to the present invention is not particularly limited as long as it is an object for the purpose of preventing or treating blood circulation-related diseases, any one can be applied.
- any one can be applied.
- monkeys, dogs, cats, rabbits, morphotes, rats, mice, cows, sheep, pigs, goats and the like but not limited to, such as, but not limited to, and can be applied to any individual.
- Another embodiment of the present invention provides a health functional food composition for preventing or improving blood circulation related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- the complex extract containing Schisandra chinensis may be added to the dietary supplement composition for the purpose of preventing or improving blood circulation related diseases such as obesity, hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, diabetes, liver disease, and the like. .
- the dietary supplement composition may include a food acceptable carrier.
- Food compositions of the present invention include all forms of functional foods, nutritional supplements, health foods and food additives, and the like. It may be prepared in various forms according to known conventional methods.
- the complex extract containing Schisandra chinensis can be added as it is or used together with other food or food ingredients, and can be suitably used according to a conventional method.
- the mixed amount of the active ingredient can be determined suitably according to the purpose of use (prevention, health or therapeutic treatment).
- the composite extract containing Schisandra chinensis in the preparation of food or beverage is added in an amount of 0.0001 to 1% by weight, preferably 0.001 to 0.1% by weight in the raw material composition.
- the amount may be used below the above range.
- Examples of foods to which the above substances can be added include dairy products including meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, beverages, teas and drinks. , Alcoholic beverages and vitamin complexes, and the like, may include all of the health food in the conventional sense.
- the health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage.
- the above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
- sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
- the ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 compositions of the present invention can be used.
- the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage.
- the proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
- the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. Although the proportion of such pulp is not critical, it is generally selected from the range of 0.01 to 10 parts by weight per 100 parts by weight of the composition of the present invention, these components can be used independently or in combination.
- Mungyeong acid Schisandra chinensis (1 kg) and dried turmeric (1 kg) were respectively refluxed at 80 ° C. for 3 hours using 15 L of 70% ethanol (EtOH), and the filtrate was concentrated under reduced pressure at 50 ° C.
- the concentrate was lyophilized to prepare Schizandra chinensis extract (340 g) and Turmeric extract (63 g).
- each of the prepared Schisandra chinensis extract and turmeric extract were mixed in a weight ratio to prepare a complex extract having a ratio of Schisandra chinensis and 4: 1, 2: 1, 1: 1, 1: 2 and 1: 4, respectively.
- Mungyeong acid Schisandra chinensis (1 kg) and dried upper leaves (1 kg) were respectively refluxed at 80 ° C. for 3 hours using 15 L of 70% ethanol (EtOH), and the filtrate was concentrated under reduced pressure at 50 ° C.
- EtOH 70% ethanol
- Each of the concentrates was lyophilized to prepare Schizandra chinensis extract (340 g) and upper leaf extract (179 g).
- each of the Schisandra chinensis extract and the upper leaf extract was mixed in a weight ratio to prepare a complex extract having a ratio of Schisandra chinensis and the upper leaf 4: 1, 2: 1, 1: 1, 1: 2 and 1: 4, respectively.
- Example 2 Evaluation of the Thrombotic Inhibitory Effect of Schisandra chinensis Extracts in Carageenan-induced Thrombus Animal Model
- Example 1-1 200 mg / kg of Schisandra chinensis extract prepared in Example 1-1 was orally administered every 3 days before carrageenan injection with different ratios of Schisandra chinensis and turmeric, and orally administered 1 hour before carrageenan injection on the day of thrombus induction. Thereafter, oral administration was performed at 23 hours, 47 hours, or 71 hours after carrageenan injection.
- tail thrombus formation length after 72 hours after carrageenan injection was measured and shown in FIG. 1.
- the tail thrombus formation length observed at 72 hours after the injection of only carrageenan into rats was 2.85 cm on average, but when the complex extract containing Schisandra chinensis was injected, the inhibition rate was 4: 1. 52%, 47% for 2: 1, 77% for 1: 1, and 63% for 1: 2, the tail blood clot length was much shorter.
- the composite extract of 1 person averaged about 1.10cm (p ⁇ 0.01) it was confirmed that it has the best thrombus inhibitory effect.
- the complex extract containing Schisandra chinensis has a very good antithrombotic activity, and in particular, the ratio of Schisandra chinensis extract has the most excellent antithrombotic activity. .
- the average tail thrombus generation length was 2.73 cm, but when injected with a complex extract containing Schisandra chinensis inhibition rate is 4: 1 39% of cases, 37% of cases of 2: 1, 69% of cases of 1: 1, 72% of cases of 1: 2, 53% of cases of 1: 4, and the length of tail blood clots was much shorter.
- the average value of tail thrombus generation length was about 1.06 cm (p ⁇ 0.001), indicating that it had the best thrombus inhibitory ability.
- the complex extract containing Schisandra chinensis has a very good antithrombotic activity, and in particular, the Schisandra chinensis extract has a very good antithrombotic activity.
- Colby's E value calculated using 36% and 21% of inhibition rate is 49
- the actual inhibition rate of the Schisandra chinensis extract is 84%, so the Schisandra chinensis extract of the present invention is much larger than the effect of the extract alone. It can be seen that there is a synergistic effect.
- the value of Colby's Formula E calculated using 36% and 41% of inhibition rate is 62, respectively.
- the actual inhibition rate of the Schisandra chinensis extract is 92%, and the Schisandra chinensis extract of the present invention is much larger than the effect of the extract alone. It can be seen that there is a synergistic effect.
- Example 2-2 In order to confirm the ex-vivo platelet aggregation inhibitory effect of the extract of Schisandra chinensis, anesthesia was measured in Example 2-2, and anesthetized the SD rat, and then blood was slowly collected from the arterial blood in the abdominal cavity to obtain 3.2% sodium sheet. After immersing the blood in the tube containing the rate anticoagulant, the collected blood was centrifuged at 1,000 rpm for 10 minutes. Isolated platelet rich plasma (PRP) was diluted with platelet poor plasma obtained by centrifugation at 3,000 rpm for 10 minutes, and then used as a platelet count of 4.0 ⁇ 10 8 .
- PRP Isolated platelet rich plasma
- the platelet aggregation inhibitory activity is an optical method for confirming platelet aggregation through PRP, and the change of the electrical resistance and the light source according to the aggregation of platelets was measured.
- 245 ⁇ l of blood was put in a cuvette and reacted for 10 minutes at 37 ° C. using a platelet agglomerate 700-2 (Chrono-Log.Havertown, PA).
- 2.5 ⁇ l of extract samples were added to each sample for reaction.
- 10 ⁇ g / ml of collagen which is a platelet aggregation promoter, was added and measured at 37 ° C. for up to 10 minutes while stirring at 1,200 rpm.
- Example 2-3 In order to confirm the ex-vivo platelet aggregation inhibitory effect of the extract of Schisandra chinensis Fructus, anesthesia was measured in Example 2-3. Blood was placed in a tube containing anticoagulant. The collected blood was centrifuged at 1,000 rpm for 10 minutes. Isolated platelet rich plasma (PRP) was diluted with platelet poor plasma obtained by centrifugation at 3,000 rpm for 10 minutes, and then used as a platelet count of 4.0 ⁇ 10 8 .
- PRP Isolated platelet rich plasma
- the platelet aggregation inhibitory activity is an optical method for confirming platelet aggregation through PRP, and the change of the electrical resistance and the light source according to the aggregation of platelets was measured.
- 245 ⁇ l of blood was put in a cuvette and reacted at 37 ° C. for 10 minutes using a platelet aggregator 700-2 (Chrono-Log.Havertown, PA).
- 2.5 ⁇ l of extract samples were added to each sample for reaction.
- 10 ⁇ g / ml of collagen which is a platelet aggregation promoter, was added and measured at 37 ° C. for up to 10 minutes while stirring at 1,200 rpm.
- the well-known complex is Schisandra chinensis, buckwheat, barley, raw yellow sulfur, aquatic herb, rat eye bean, pork potato, red bean, red dog, turmeric, mulberry leaf, dermis, gujeolcho, chaga, ogapi, sewage, jujube, octopus, acorn It is a complex extract known to inhibit blood cholesterol and have blood vessel purification functions.
- the known complex has almost no difference from the thrombus generation length when only carrageenan is injected, and thus, it has been found that there is almost no inhibition of thrombus generation.
- Schisandra chinensis (1: 1) complex extract and Schisandra chinensis (1: 2) complex extract of the present invention as shown in Example 2, the average value of tail thrombus generation length was 1.10 cm and 1.06 cm, respectively.
- the antithrombotic activity was significantly higher than that of only carrageenan injection, and it was confirmed that the antithrombotic activity was significantly superior to that of the known complex.
- the Schizandra chinensis-containing extract of the present invention and the well-known complex were tested in the same manner as in Example 3 to compare the effect of inhibiting platelet aggregation.
- the known complex was tested in two concentrations of 200 mg / kg and 400 mg / kg, using aspirin (25 mg / kg) as a positive control and collagen (10 ⁇ g / ml) as a platelet aggregation stimulating substance. It was. The result is as shown in FIG.
- the known complexes have a statistical significance of 88.8% and 86.8% at the 200 mg / kg low dose when the S. aureus-S. Turmeric and S. aureus complexes are 100% when platelets are aggregated with collagen.
- the known complex (prior art) showed 105.8% at the 200 mg / kg dose, which did not have a platelet aggregation inhibitory effect, and a high inhibitory effect of 92.5% at a high dose of 400 mg / kg. It can be seen that it does not have a known complex, although it contains all 17 other active ingredients in addition to turmeric and lettuce in Schizandra chinensis, the effect was significantly lower than the extract of the present invention.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition comprising a Schisandrae Fructus-containing composite extract as an active ingredient for preventing or treating a blood circulation-related disease, to a method for treating a blood circulation-related disease, the method comprising a step for administering the composition to a subject in need thereof, and to a quasi-drug composition, feed additive, and health functional food composition comprising a Schisandrae Fructus-containing composite extract for preventing or alleviating a blood circulation-related disease. The Schisandrae Fructus-containing composite extract of the present invention, particularly, a Schisandrae Fructus-Curcumae Longae Rhizoma composite extract or a Schisandrae Fructus-Mori Folium composite extract inhibits thrombogenesis and effectively suppresses platelet aggregation, and thus can be effectively used in the prevention or treatment of a blood circulation-related disease. In addition, the composition can be applied and used as a quasi-drug composition, health functional food composition, or feed additive for preventing or alleviating a blood circulation-related disease.
Description
본 발명은 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 치료용 조성물, 상기 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는 혈액순환 관련 질환의 치료 방법, 오미자를 함유하는 복합 추출물을 포함하는 혈액순환 관련 질환의 예방 또는 개선용 의약외품 조성물, 사료첨가제 및 건강기능식품 조성물에 관한 것이다.The present invention is a composition for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient, a method for treating a blood circulation-related disorder comprising administering the composition to an individual in need thereof, Schisandra chinensis It relates to a quasi-drug composition, feed additives and health functional food composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing.
최근 경제적 발전과 식습관 등의 변화에 따라 고지혈증, 고혈압, 동맥경화, 심근경색, 뇌졸중 또는 뇌경색 등의 다양한 질환을 포함하는 혈액순환 관련 질환의 발병이 급증하고 있는 상황이다. 이와 같은 질환들은 각각 발생하기도 하지만 일반적으로는 서로 밀접한 관련을 맺고 있으면서 여러 증상들을 동반하여 발생되는 경우가 대부분이다.Recently, the development of blood circulation-related diseases including a variety of diseases such as hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke or cerebral infarction is increasing rapidly according to economic development and changes in eating habits. Although these diseases occur individually, they are usually closely related to each other and often accompanied by various symptoms.
혈액순환 관련 질환 중 고지혈증은 혈중 콜레스테롤과 같은 지질성분이 증가하면서 혈액의 흐름이 원활하지 않게 되고, 동맥벽에 지질성분들이 부착되면서 발병하는 질환으로, 만성적인 염증반응과 동맥내벽이 좁아지면서 혈관이 굳어지는 동맥경화가 유발되고, 장기적으로는 이로부터 생성된 혈전이 심장관상동맥이나 뇌혈관 등을 막아 심근경색, 뇌졸중이나 뇌경색 등을 일으키는 원인이 된다. 현재 고지혈증 치료제는 간에서의 콜레스테롤의 합성과정에 중요한 역할을 하고 있는 HMG-CoA 환원효소(HMG-CoA reductase)에 대하여 억제활성을 갖고 있는 스타틴 계열의 약물들이 사용되고 있으나, 상기 약물을 장기간 사용할 경우 간독성이나 근육독성 등의 부작용이 있는 것으로 알려져 있다.Hyperlipidemia is a disease caused by increased blood lipids such as cholesterol in blood circulation and blood lipids attached to the artery wall. Chronic inflammatory reactions and narrowing of the arterial wall cause blood vessels to harden. Atherosclerosis is induced, and in the long run, clots generated therefrom block coronary arteries and cerebrovascular vessels, causing myocardial infarction, stroke and cerebral infarction. Currently, drugs for treating hyperlipidemia are used as statin drugs that have inhibitory activity against HMG-CoA reductase, which plays an important role in the synthesis of cholesterol in the liver. It is known to have side effects such as muscle toxicity.
또한, 고혈압은 동맥의 혈압이 만성적으로 높은 상태를 의미하는 질환으로, 18세 이상의 성인에서 수축기 혈압이 140mmHg 이상이거나 확장기 혈압이 90mmHg이상인 경우이고, 동맥경화는 콜레스테롤, 인지질, 칼슘 등을 함유한 지방성 물질(plaque)이 혈관 내막에 축적됨으로써, 동맥이 단단해지고 탄력성을 잃고 좁아지는 질환으로, 결국 혈액공급이 저해되거나 압력이 높아져 동맥이 파열, 박리 등이 일어나는 상태를 의미한다. 현재 고혈압 치료제로는 레닌 저해제 약물, 안지오텐신전환효소 활성 저해 약물, 또는 안지오텐신과 안지오텐신 수용체간의 결합을 저해하는 약물들이 개발되어 사용되고 있고, 동맥경화 치료제로는 HMG-CoA reductase 저해제인 다양한 스타틴 (statin)류 등이 개발되어 있으나, 상기 치료제 역시 장기간 사용시 부작용이 있다고 알려져 있어 여전히 보다 효과적인 치료제의 개발에 대한 필요성이 요구되고 있다.In addition, hypertension is a condition in which the arterial blood pressure is chronically high, and systolic blood pressure is 140 mmHg or more or diastolic blood pressure is 90 mmHg or more in an adult 18 years or older, and arteriosclerosis is a fat containing cholesterol, phospholipids, and calcium. Plaque accumulates in the vascular lining, causing the arteries to become rigid, losing elasticity, and narrowing. Eventually, the arterial rupture, detachment, etc. occur due to impaired blood supply or increased pressure. Currently, drugs for inhibiting hypertension, drugs for inhibiting angiotensin converting enzyme activity or drugs for inhibiting binding between angiotensin and angiotensin receptors, have been developed and used, and various statins, which are HMG-CoA reductase inhibitors, are used for the treatment of atherosclerosis. And the like have been developed, the therapeutic agent is also known to have side effects when used for a long time, there is still a need for the development of a more effective therapeutic agent.
이러한 배경 하에, 본 발명자들은 고지혈증, 고혈압, 동맥경화, 심근경색, 뇌졸중 또는 뇌경색 등을 포함하는 혈액순환 관련 질환에 부작용이 없고 효과적인 천연 물질을 개발하고자 예의 노력한 결과, 오미자를 함유하는 복합 추출물, 특히, 오미자-강황 복합 추출물 또는 오미자-상엽 복합 추출물이 혈전 생성을 억제하고, 혈소판 응집 억제능이 있어 혈액순환 관련 질환을 예방, 개선 또는 치료하는 데에 효과가 있음을 확인함으로써 본 발명을 완성하였다.Against this background, the present inventors have made efforts to develop natural substances that have no side effects and are effective in blood circulation-related diseases including hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke or cerebral infarction, etc. The present invention was completed by confirming that Schizandra chinensis-C extract or Schizandra chinensis complex extract inhibited thrombus formation and inhibited platelet aggregation, which is effective in preventing, improving or treating blood circulation-related diseases.
본 발명의 목적은 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 치료용 약학 조성물을 제공하는 것이다.An object of the present invention to provide a pharmaceutical composition for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
본 발명의 다른 하나의 목적은 상기 혈액순환 관련 질환의 예방 또는 치료용 약학 조성물을 이를 필요로 하는 개체에게 투여하는 단계를 포함하는, 혈액순환 관련 질환의 치료 방법을 제공하는 것이다.Another object of the present invention is to provide a method for treating a blood circulation related disease, comprising administering the pharmaceutical composition for preventing or treating the blood circulation related disease to an individual in need thereof.
본 발명의 또 다른 하나의 목적은 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 개선용 의약외품 조성물을 제공하는 것이다.Another object of the present invention to provide a quasi-drug composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 개선용 사료첨가제를 제공하는 것이다.Another object of the present invention to provide a feed additive for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention to provide a health functional food composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
본 발명의 오미자를 함유하는 복합 추출물, 특히, 오미자-강황 복합 추출물 또는 오미자-상엽 복합 추출물은 혈전 생성을 억제하고 혈소판 응집을 효과적으로 억제하여 혈액순환 관련 질환의 예방 또는 치료에 효과적으로 사용될 수 있다. 또한, 상기 조성물을 혈액순환 관련 질환의 예방 또는 개선용 의약외품 조성물, 건강기능식품 조성물, 또는 사료 첨가제로 응용하여 사용할 수 있다.The complex extract containing Schisandra chinensis of the present invention, in particular, Schisandra chinensis extract or Schisandra chinensis complex extract can be effectively used for the prevention or treatment of blood circulation-related diseases by inhibiting thrombus formation and effectively inhibiting platelet aggregation. In addition, the composition can be used as a quasi-drug composition, health functional food composition, or feed additives for the prevention or improvement of blood circulation-related diseases.
도 1은 다양한 비율의 오미자-강황 복합 추출물의 혈전생성 억제능을 나타내는 그래프이다.1 is a graph showing the thrombus formation inhibitory ability of Schizandra chinensis extract of various ratios.
도 2는 다양한 비율의 오미자-상엽 복합 추출물의 혈전생성 억제능을 나타내는 그래프이다.Figure 2 is a graph showing the thrombus generation inhibitory ability of Schizandra chinensis compound extract of various ratios.
도 3은 오미자, 강황의 단독 추출물 및 오미자-강황 복합 추출물의 혈전생성 억제능을 나타내는 그래프이다.Figure 3 is a graph showing the antithrombotic activity of Schizandra chinensis, Turmeric alone and Schizandra chimus extract.
도 4는 오미자, 상엽의 단독 추출물 및 오미자-상엽 복합 추출물의 혈전생성 억제능을 나타내는 그래프이다.Figure 4 is a graph showing the thrombus formation inhibitory ability of Schizandra chinensis, S. chinensis extract and Schizandra chinensis combined extract.
도 5는 다양한 비율의 오미자-강황 복합 추출물의 혈소판 응집 억제능을 나타내는 그래프이다.Figure 5 is a graph showing the platelet aggregation inhibitory ability of Schizandra chinensis complex extract of various ratios.
도 6은 다양한 비율의 오미자-상엽 복합 추출물의 혈소판 응집 억제능을 나타내는 그래프이다.Figure 6 is a graph showing the platelet aggregation inhibitory ability of Schizandra chinensis compound extract of various ratios.
도 7은 공지의 오미자 함유 19종 복합 추출물과 본 발명의 오미자 복합 추출물의 혈전 생성 억제능을 비교한 그래프이다.Figure 7 is a graph comparing the thrombus generation inhibitory ability of the known Schizandra-containing 19 species complex extract and Schizandra complex extract of the present invention.
도 8은 공지의 오미자 함유 19종 복합 추출물과 본 발명의 오미자 복합 추출물의 혈소판 응집 억제능을 비교한 그래프이다.Figure 8 is a graph comparing the platelet aggregation inhibitory ability of the known Schizandra-containing 19 species complex extract and Schizandra complex extract of the present invention.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는 오미자를 함유하는 복합 추출물, 구체적으로는, 오미자-강황 복합 추출물 또는 오미자-상엽 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 치료용 약학 조성물을 제공한다.One aspect of the present invention for achieving the above object is for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis, specifically, Schisandra chinensis complex extract or Schisandra chinensis complex extract as an active ingredient. It provides a pharmaceutical composition.
또한, 본 발명은 오미자를 함유하는 복합 추출물, 구체적으로는 오미자-강황 복합 추출물 또는 오미자-상엽 복합 추출물을 유효성분으로 포함하는 조성물의 혈액순환 관련 질환의 예방 또는 치료용도를 제공한다.In addition, the present invention provides a preventive or therapeutic use of blood circulation-related diseases of the composition comprising a complex extract containing Schisandra chinensis, specifically Schisandra chinensis complex extract or Schisandra chinensis extract as an active ingredient.
본 발명에서의 용어, "오미자(Schisandra chinesis)"는 지름이 약 1cm의 공 모양의 짙은 붉은 과실을 의미하는 것으로, 속에는 붉은 즙과 불그스레한 갈색 종자가 1~2개 들어있다. 종류로는 북오미자, 남오미자, 흑오미자 등이 있으며, 시잔드린, 고미신, 시트럴, 사과산, 시트르산 등의 성분이 들어 있어 심장을 강하게 하고 혈압을 내리며, 면역력을 높여주어 강장제로 사용될 수 있다고 알려져 있다. 오미자는 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 채취 또는 재배된 것을 사용할 수 있으나, 이에 제한되는 것은 아니다.The term " Schisandra chinesis " in the present invention means a ball-shaped dark red fruit having a diameter of about 1 cm, and contains 1 to 2 red juices and reddish brown seeds. Types include North Schisandra chinensis, South Schisandra chinensis and Black Schisandra chinensis, and it contains ingredients such as cezandrarin, gomisin, citric acid, malic acid and citric acid.It is known to be used as a tonic by strengthening the heart, lowering blood pressure and enhancing immunity. have. Schisandra may be purchased and used commercially, or may be collected or grown in nature, but is not limited thereto.
본 발명에서의 용어, "강황(Curcumae Longae Rhizoma)"은 울금(Tumeric)이라 불리기도 하며, 한방에서 한약재로 사용되어온 생강목 생강과의 다년생 초본을 의미한다. 강황은 매운 맛과 쓴 맛을 가지고, 뿌리줄기의 겉은 연한 노란색이며, 속은 주홍빛으로 장뇌 같은 향기가 난다. 또한, 꽃 이삭이 잎보다 먼저 나오며, 4~6월에 잎 겨드랑이에서 노란 꽃이 피운다고 알려져 있다. 강황 또한 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 채취 또는 재배된 것을 사용할 수 있으나, 이에 제한되는 것은 아니며, 강황의 줄기, 잎 또는 뿌리 부분을 사용할 수 있으나, 이에 제한된 것은 아니다.The term " curcumae Longae Rhizoma " in the present invention, also called ulumum (Tumeric), means a perennial herb of Ginger-necked ginger family, which has been used as a herbal medicine in oriental medicine. Turmeric has a spicy and bitter taste, the outside of the rhizome is light yellow, and the inside is scarlet and has a camphor-like scent. It is also known that flowering ear comes out before the leaves, and yellow flowers bloom in the leaf axes in April and June. Turmeric may also be purchased and used commercially, or may be one that is collected or cultivated in nature, but is not limited thereto. The stem, leaf, or root portion of turmeric may be used, but is not limited thereto.
본 발명에서의 용어, "상엽(Mulberry leaf)"은 장미목 뽕나무과에 속하는 낙엽 활엽 교목인 뽕나무(Morus alba L.)의 잎을 의미하는 것으로, 한의학적으로는 뽕나무의 잎을 건조하여 수득한 약재를 말한다. 뽕나무의 잎은 매년 채취가 가능하고, 플라보노이드, 알칼로이드와 같은 2차 대사 산물들을 많이 함유하고 있어 산업적으로 이용가치가 높은 약재이다. 상엽 또한 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 채취 또는 재배된 것을 사용할 수 있으나, 이에 제한되는 것은 아니며, 사용되는 부위는 상엽이 의미하는 바와 같이 뽕나무의 잎 부위를 사용할 수 있다.The term "mulberry leaf " in the present invention refers to the leaves of the mulberry (Morus alba L.), which is a deciduous broad-leaved arboreous tree belonging to the rose family Mulberry family, and in Oriental medicine, it refers to a medicinal herb obtained by drying the leaves of the mulberry tree. . Mulberry leaves can be harvested annually and contain high amounts of secondary metabolites such as flavonoids and alkaloids. The upper leaf may also be purchased and used commercially, or may be used collected or cultivated in nature, but is not limited thereto, and the portion used may use the leaf of the mulberry leaf as the meaning of the upper leaf.
본 발명에서 용어, "추출물"은 상기 오미자를 함유하는 추출물로서, 오미자를 단독으로 추출한 추출물을 포함할 수 있다. 또한, 본 발명에서 용어 "복합 추출물"은 두 가지 이상의 물질을 함유하는 추출물을 의미하는 것으로, 구체적으로는, 오미자 외 다른 물질을 하나 이상 포함하여 추출한 추출물, 보다 구체적으로는, 오미자-강황 복합 추출물 또는 오미자-상엽 복합 추출물을 의미하나, 이에 제한된 것은 아니다. 상기 복합 추출물은 오미자와 오미자 외 다른 물질을 혼합한 후 함께 추출한 추출물과 오미자와 오미자 외 다른 물질을 각각 추출하여 추출물을 제조한 후 그 추출물을 혼합한 추출물, 구체적으로는 오미자에 강황 또는 상엽을 혼합한 후 추출한 추출물과 오미자 추출물에 강황 또는 상엽 추출물을 혼합한 추출물을 포함할 수 있으나, 이에 제한된 것은 아니다. In the present invention, the term "extract" is an extract containing Schisandra chinensis, and may include an extract extracted Schisandra chinensis alone. In addition, the term "composite extract" in the present invention means an extract containing two or more substances, specifically, an extract containing one or more substances other than Schisandra chinensis, more specifically, Schisandra chinensis extract Or Schizandra chinensis compound extract, but is not limited thereto. The complex extract is a mixture of Schisandra chinensis and other substances other than Schisandra chinensis extract, and Schicho and Schisandra chinensis extract, respectively, to prepare an extract and then to extract the extract, specifically, turmeric or lettuce in Schisandra chinensis It may include, but is not limited to, an extract obtained by mixing turmeric or upper leaf extract with the extracted extract and Schisandra chinensis extract.
상기 추출물은 각 성분의 분쇄물을 건조 중량의 약 1 내지 20배, 구체적으로는 약 3 내지 5배에 달하는 부피의 물, 메탄올, 에탄올 등과 같은 탄소수 1(C1) 내지 4(C4)의 저급 알콜과 같은 극성 용매 또는 이들의 약 1:0.1 내지 1:10의 혼합비를 갖는 혼합용매로 용출할 수 있으나, 그에 제한된 것은 아니며, 추출 온도는 20℃ 내지 100℃, 구체적으로는 60℃ 내지 100℃에서 추출할 수 있으나, 이에 제한된 것은 아니다. 또한, 추출기간은 약 1시간 내지 4일 동안 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 추출방법을 사용하여 추출한 추출물일 수 있으나, 본 발명의 혈액순환 관련 질환의 치료 효과를 나타낼 수 있는 추출물인 한, 이에 제한되지는 않고, 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이들 조정제물 또는 정제물을 모두 포함할 수 있다. 상기 오미자 추출물, 강황 추출물, 상엽 추출물은 천연, 잡종, 변종식물의 다양한 기관으로부터 추출될 수 있고, 예를 들어 뿌리, 지상부, 줄기, 잎, 꽃, 열매의 몸통, 열매의 껍질뿐만 아니라 식물 조직 배양물로부터 추출 가능하다.The extract is a low alcohol of 1 (C1) to 4 (C4) carbon, such as water, methanol, ethanol, etc. in a volume of about 1 to 20 times the dry weight, specifically about 3 to 5 times the dry weight of each component Elution with a polar solvent such as or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, but is not limited thereto, the extraction temperature is 20 ℃ to 100 ℃, specifically 60 ℃ to 100 ℃ Can be extracted, but is not limited thereto. In addition, the extraction period may be an extract extracted using an extraction method such as hot water extraction, cold needle extraction, reflux cooling extraction or ultrasonic extraction for about 1 hour to 4 days, but may exhibit a therapeutic effect of the blood circulation-related diseases of the present invention. As long as the extract is present, it is not limited thereto, and may include all extracts, dilutions or concentrates of the extracts, dried products obtained by drying the extracts, or all of these modifiers or purified products. The Schisandra chinensis extract, turmeric extract, upper leaf extract can be extracted from various organs of natural, hybrid, mutant plants, for example, roots, ground, stems, leaves, flowers, trunks of fruits, bark of fruit as well as plant tissue culture Extractable from water.
본 발명의 일 실시예에서는 문경 건오미자를 구매하여 분쇄한 후, 오미자 분쇄물 1kg을 15L의 70% 에탄올 수용액으로 80℃에서 3시간 추출 후 50℃에서 감압 농축하였고, 강황 및 상엽도 건조된 약재를 구매하여 상기와 같은 방법으로 추출 및 감압 농축하였다. 또한, 상기 농축액을 동결건조하여 최종적으로 오미자 추출물, 강황 추출물 및 상엽 추출물 각각 340g, 63g 및 179g을 획득한 후, 각각의 추출물을 설정된 비율에 따라 혼합하여 복합 추출물을 제조하였다.In one embodiment of the present invention, after purchasing and grinding Mungyeong dried Schisandra chinensis, 1 kg of Schisandra chinensis was extracted with 15 L of 70% ethanol aqueous solution at 80 ° C. for 3 hours, and then concentrated under reduced pressure at 50 ° C., which was dried turmeric and upper leaf. It was purchased and extracted in the same manner as above and concentrated under reduced pressure. In addition, the concentrate was lyophilized to finally obtain 340 g, 63 g, and 179 g of Schizandra chinensis extract, turmeric extract, and upper leaf extract, respectively, and then, each extract was mixed according to a set ratio to prepare a composite extract.
상기 오미자 및 강황 복합 추출물은 오미자 추출물과 강황 추출물을 0.1 내지 10 : 1의 중량비로 포함할 수 있으며, 구체적으로는, 0.5 내지 2 : 1의 중량비로 포함할 수 있으나, 이에 제한된 것은 아니다. 또한, 상기 오미자 및 상엽 복합 추출물은 오미자 추출물과 상엽 추출물을 0.1 내지 10 : 1의 중량비로 포함할 수 있으며, 구체적으로는, 0.25 내지 1 : 1의 중량비로 포함할 수 있으나, 이에 제한된 것은 아니다.The Schisandra chinensis extract and turmeric extract may include Schisandra chinensis extract and turmeric extract in a weight ratio of 0.1 to 10: 1, specifically, but may include 0.5 to 2: 1 by weight, but is not limited thereto. In addition, the Schisandra chinensis and upper leaf complex extract may include Schisandra chinensis extract and the upper leaf extract in a weight ratio of 0.1 to 10: 1, specifically, may comprise a weight ratio of 0.25 to 1: 1, but is not limited thereto.
상기 조성물은 혈전 생성을 억제할 수 있으며, 특히, 혈소판 응집 억제능이 있어 혈전증(thrombosis)을 포함하는 다수의 혈액순환 관련 질환의 예방 또는 치료용으로 사용될 수 있다.The composition may inhibit thrombus formation, and in particular, may have a platelet aggregation inhibitory ability, and thus may be used for the prevention or treatment of a number of blood circulation-related diseases including thrombosis.
본 발명에서의 용어, "혈액순환 관련 질환"은 대사에 문제가 있어 발생하거나, 혈전에 의하여 유발되는 다양한 질환을 통칭하는 것으로, 본 발명의 오미자를 함유하는 복합 추출물을 유효성분으로 치료 또는 예방할 수 있는 질환은 제한 없이 포함되나, 그 예로 고지혈증, 고혈압, 동맥경화, 심근경색, 뇌졸중 및 뇌경색으로 이루어진 군에서 선택된 하나 이상의 질환일 수 있다.As used herein, the term "blood circulation related disease" refers to various diseases caused by metabolic problems or caused by blood clots, and the complex extract containing Schisandra chinensis of the present invention can be treated or prevented with an active ingredient. Diseases that are present include, but are not limited to, one or more diseases selected from the group consisting of hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke and cerebral infarction.
본 발명에서 용어, "고지혈증"은 중성 지방과 콜레스테롤 등의 지방대사가 제대로 이루어지지 않아 혈액 중에 지방량이 많아 유발되는 질환을 말하며, 구체적으로는, 혈액 내의 중성지방, LDL 콜레스테롤, 인지질 및 유리 지방산 등의 지질 성분이 증가된 상태로서 발생빈도가 높은 고콜레스테롤혈증 또는 고중성지방혈증을 포함할 수 있으나, 이에 제한된 것은 아니다.In the present invention, the term "hyperlipidemia" refers to a disease caused by a large amount of fat in the blood due to poor metabolism such as triglycerides and cholesterol, specifically, triglycerides in the blood, LDL cholesterol, phospholipids and free fatty acids, etc. As the lipid component of the increased state may include high cholesterol or hypertriglyceridemia, but is not limited thereto.
본 발명에서 용어, "고혈압"은 동맥의 혈압이 만성적으로 높은 상태로서, 18세 이상의 성인에서 수축기 혈압이 140mmHg 이상이거나 확장기 혈압이 90mmHg이상인 경우를 말하며, 비만 등에 의해 발생하기도 한다.In the present invention, the term "hypertension" refers to a state in which the arterial blood pressure is chronically high, and the systolic blood pressure is 140 mmHg or more or the diastolic blood pressure is 90 mmHg or more in an adult 18 years or older, and may be caused by obesity or the like.
본 발명에서 용어, "동맥경화"는 콜레스테롤, 인지질, 칼슘 등을 함유한 지방성 물질 (plaque)이 혈관 내막에 축적되어 동맥이 단단해지고 탄력성을 잃고 좁아져 유발되는 질환으로, 혈액공급이 저해되거나 압력이 높아져 동맥이 파열 또는 박리 등이 일어나는 상태를 의미한다.In the present invention, the term "arteriosclerosis" is a disease caused by the accumulation of fatty substances (plaque) containing cholesterol, phospholipids, calcium, etc. in the vascular lining, which causes the arteries to become hard, lose elasticity, and narrow, and thus inhibit blood supply or pressure. This means that the artery is ruptured or peeled off.
본 발명에서 용어, "심근경색"은 심장혈관이 혈전, 연축 등의 원인으로 갑자기 막혀 심장 근육이 손상되는 질환을 의미하며, "뇌졸중"은 뇌기능의 부분적 또는 전체적으로 급속히 발생한 장애가 상당 기간 이상 지속되는 것으로, 뇌혈관의 병 이외에는 다른 원인을 찾을 수 없는 상태를 일컫는 질환을 말하며, 구체적으로는, 뇌혈관이 막혀서 발생하는 질환을 뇌경색 또는 허혈성 뇌졸중이라 하고, 뇌혈관의 파열로 인해 뇌 조직 내부로 혈액이 유출되어 발생하는 질환을 뇌출혈 또는 출혈성 뇌졸중이라 한다.As used herein, the term "myocardial infarction" refers to a disease in which the heart muscle is suddenly blocked due to blood clots, spasms, or the like, and the heart muscle is damaged. It refers to a condition that refers to a condition in which no cause can be found other than a disease of cerebrovascular vessels. Specifically, a disease caused by blockage of the cerebrovascular vessels is called a cerebral infarction or ischemic stroke, and blood flows into the brain tissue due to the rupture of the cerebrovascular vessel. This outflow disease is called cerebral hemorrhage or hemorrhagic stroke.
본 발명의 일 실시예에 따르면, 랫트의 혈액에서 수득한 혈소판에 상기 오미자-강황 복합 추출물 또는 오미자-상엽 복합 추출물을 비율을 달리하여 반응시킨 다음, 혈소판 응집 촉진물질인 콜라겐을 가하여 혈소판의 응집을 유도한 결과, 오미자-강황의 혼합비가 0.25 내지 4 : 1, 오미자-상엽의 혼합비가 0.25 내지 4 : 1인 복합 추출물에서 우수한 혈소판 응집 억제능을 가짐을 확인할 수 있었다. 또한, 수득한 오미자-강황 복합 추출물과 오미자-상엽 복합 추출물에서, 오미자-강황 또는 오미자-상엽의 비율을 달리한 복합 추출물을 랫트에 경구투여하고, 이 후 혈전 생성을 유도하는 카라기난(carageenan)을 랫트에 주사한 후 일정 시간이 지나고 나서 꼬리에 형성된 혈전을 비교해 본 결과, 오미자-강황 복합 추출물과 오미자-상엽 복합 추출물에서 혈전 생성이 현저히 억제되는 것을 확인함으로서, 본 발명의 오미자를 함유하는 복합 추출물이 혈액순환 관련 질환에 대하여 현저히 우수한 효과를 가짐을 확인할 수 있었다.According to an embodiment of the present invention, the platelet obtained from the blood of the rat is reacted at different ratios of the Schizandra chinensis complex extract or Schizandra chinensis complex extract, and then platelet aggregation is promoted by adding collagen as a platelet aggregation promoter. As a result of the induction, it was confirmed that the mixture ratio of Schisandra chinensis was 0.25 to 4: 1, and that the Schisandra chinensis mixture ratio of 0.25 to 4: 1 has excellent platelet aggregation inhibitory ability. In addition, in the obtained Schisandra chinensis-harmony extract and Schisandra chinensis-leaf extract, oral administration of a complex extract having a different ratio of Schisandra chinensis or Schisandra chinensis to the rats, and then carrageenan (carageenan) to induce thrombus formation After a certain period of time after injection into rats, the blood clots formed in the tails were compared. As a result, it was confirmed that thrombus formation was significantly inhibited in the Schizandra chinensis-complex extract and Schizandra chinensis extract, the complex extract containing Schizandra chinensis of the present invention. It was confirmed that the blood circulation-related diseases have a remarkably excellent effect.
이로써, 본 발명의 오미자를 함유하는 복합 추출물, 구체적으로는, 오미자-강황 복합 추출물 또는 오미자-상엽 복합 추출물은 혈액순환 관련 질환, 특히 혈전에 의하여 유발되는 질환의 예방 또는 치료를 위하여 사용될 수 있다.Thus, the complex extract containing Schisandra chinensis of the present invention, specifically, Schisandra chinensis complex extract or Schisandra chinensis complex extract can be used for the prevention or treatment of diseases related to blood circulation, in particular diseases caused by blood clots.
본 발명에서 사용되는 용어, "예방"은 본 발명에 따른 조성물의 투여로 고지혈증, 고혈압, 동맥경화, 심근경색, 뇌졸중, 뇌경색 등의 혈액순환 관련 질환의 발병을 억제 또는 지연시키는 모든 행위를 말한다. 본 발명에서 사용되는 용어, "치료"는 본 발명에 따른 조성물의 투여로 상기 질환들의 증세가 호전되거나 이롭게 변경되는 모든 행위를 말한다.As used herein, the term "prevention" refers to any action that inhibits or delays the development of blood circulation-related diseases such as hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke, and cerebral infarction by administration of a composition according to the present invention. As used herein, the term "treatment" refers to any action by which administration of a composition according to the present invention improves or advantageously alters the symptoms of the diseases.
또한, 본 발명의 일 실시예에 따른 약학 조성물에 포함된 상기 오미자를 함유하는 복합 추출물의 함량은 특별히 이에 제한되지는 않으나, 최종 조성물 총중량을 기준으로 0.0001 내지 50중량%, 보다 구체적으로는 0.01 내지 5중량%의 함량으로 포함할 수 있다. In addition, the content of the complex extract containing Schisandra chinensis contained in the pharmaceutical composition according to an embodiment of the present invention is not particularly limited thereto, but is 0.0001 to 50% by weight based on the total weight of the final composition, more specifically 0.01 to It may be included in an amount of 5% by weight.
본 발명의 구체적인 양태로서의 본 발명의 조성물은 약학 조성물이다. 상기 본 발명의 조성물이 약학 조성물인 경우 상기 조성물은 약학적으로 허용 가능한 담체를 포함할 수 있다.Compositions of the invention as specific embodiments of the invention are pharmaceutical compositions. When the composition of the present invention is a pharmaceutical composition, the composition may include a pharmaceutically acceptable carrier.
약학적으로 허용 가능한 담체를 포함하는 상기 조성물은 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. The composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
상기 약제학적 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 및 좌제으로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가질 수 있다.The pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have one formulation.
상기 본 발명의 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에서 용어, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is defined as the type and severity, age, sex, Activity, sensitivity to drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
본 발명에 따른 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 조성물의 통상적인 1일 투여량은 10 내지 1,000 mg/kg, 바람직하게는 10 내지 500 mg/kg의 범위일 수 있고, 1회 또는 수 회로 나누어 투여할 수 있다.A typical daily dosage of a composition comprising a complex extract containing Schisandra chinensis according to the invention as an active ingredient may range from 10 to 1,000 mg / kg, preferably 10 to 500 mg / kg, once or It can be administered in several divided doses.
본 발명의 고지혈증, 고혈압, 동맥경화, 심근경색, 뇌졸중, 뇌경색 등의 혈액순환 관련 질환의 예방제 또는 치료제는, 매일 투여 또는 간헐적으로 투여해도 좋고, 1일당 투여 횟수는 1회 또는 2~3회로 나누어 투여하는 것이 가능하다. 두 유효성분이 각각 단제인 경우의 투여횟수는 같은 횟수여도 좋고, 다른 횟수로 해도 된다. 또한, 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The prophylactic or therapeutic agent for blood circulation-related diseases such as hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke and cerebral infarction may be administered daily or intermittently, and the number of administrations per day is divided once or twice or three times. It is possible to administer. The frequency of administration in the case where the two active ingredients are single drugs may be the same or different times. In addition, it is important to take into account all of the above factors and to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.
본 발명의 다른 하나의 양태는 오미자를 함유하는 복합 추출물을 이를 필요로 하는 개체에게 투여하는 단계를 포함하는, 혈액순환 관련 질환의 치료 방법을 제공한다.Another aspect of the invention provides a method of treating a blood circulation related disease, comprising administering a complex extract containing Schisandra chinensis to a subject in need thereof.
본 발명에서 용어, "개체"는 혈액순환 관련 질환이 이미 발병하였거나 발병할 수 있는 인간을 포함한 모든 동물을 의미하고 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 조성물을 개체에게 투여함으로써, 상기 질환을 효과적으로 예방 및 치료할 수 있다. 상기 개체는 개, 소, 말, 토끼, 마우스, 랫트, 닭 또는 인간을 포함하는 포유류 전체를 의미하나, 상기 예에 의해 본 발명의 포유류가 한정되는 것은 아니다.As used herein, the term "individual" refers to all animals including humans who have already developed or may have a blood circulation related disease, and by administering to the subject a composition comprising a complex extract containing Schisandra chinensis as an active ingredient, the disease Can be effectively prevented and treated. The subject means an entire mammal including a dog, cow, horse, rabbit, mouse, rat, chicken or human, but the mammal of the present invention is not limited to the above examples.
본 발명 조성물의 개별적인 투약의 최적량 및 투약 간격은 치료되고 있는 병의 성질 및 정도, 투여 제형, 경로 및 부위, 그리고 치료되고 있는 특정 환자의 나이와 건강상태에 의해 결정될 것이고, 의사가 궁극적으로 사용될 적절한 투약을 결정할 것이라는 것은 당해 분야의 당업자가 알 수 있을 것이다. 이러한 투약은 적절할 정도로 자주 반복될 수 있다. 부작용이 생긴다면, 보통의 임상 진료에 따라서 투여량 및 빈도를 변경하거나 또는 감소시킬 수 있다.The optimal amount and dosage interval of the individual doses of the composition of the present invention will be determined by the nature and extent of the disease being treated, the dosage form, the route and site, and the age and health of the particular patient being treated and ultimately used by the physician. It will be appreciated by those skilled in the art that the appropriate dosage will be determined. Such dosing can be repeated as often as appropriate. If side effects occur, the dosage and frequency can be altered or reduced in accordance with normal clinical practice.
상기 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 투여될 수 있다. 본 발명의 조성물은 목적하는 바에 따라 복강내 투여, 정맥내 투여, 피하 투여, 피내 투여, 경구 투여될 수 있으나, 이에 제한되지는 않는다. 또한 상기 조성물은 활성 물질이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다.The route of administration of the composition may be administered via any general route as long as it can reach the desired tissue. The composition of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, subcutaneous administration, intradermal administration, oral administration. The composition may also be administered by any device in which the active agent may migrate to the target cell.
본 발명의 또 다른 하나의 양태는 상기 복합 조성물을 유효성분으로 포함하는 의약외품 조성물을 제공한다.Another aspect of the present invention provides a quasi-drug composition comprising the complex composition as an active ingredient.
본 발명에서 용어, "오미자를 함유하는 복합 추출물"에 관해서는 상기에서 설명한 바와 같다. 보다 구체적으로, 본 발명의 조성물은 혈액순환 관련 질환의 예방 또는 개선을 목적으로, 의약외품 조성물에 첨가될 수 있다.In the present invention, the term "complex extract containing Schisandra chinensis" is as described above. More specifically, the composition of the present invention may be added to the quasi-drug composition for the purpose of preventing or improving blood circulation related diseases.
본 발명에서의 용어, "개선"은 본 발명의 오미자를 함유하는 복합 추출물을 포함하는 의약외품 조성물을 적용하여, 고지혈증 또는 동맥경화와 같은 혈액순환 관련 질환의 증상을 완화시키는 효과를 나타내는 것을 의미한다.As used herein, the term " improvement " refers to an effect of alleviating the symptoms of blood circulation-related diseases such as hyperlipidemia or arteriosclerosis by applying a quasi-drug composition comprising a complex extract containing Schizandra chinensis of the present invention.
본 발명에서 용어, "의약외품"은 사람이나 동물의 질병을 치료, 경감, 처치 또는 예방할 목적을 사용되는 섬유, 고무제품 또는 이와 유사한 것, 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니하며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염형 예방을 위하여 살균, 살충 및 이와 유사한 용도로 사용되는 제제 중 하나에 해당하는 물품으로서, 사람이나 동물의 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것 및 사람이나 동물의 구조와 기능에 약리학적 영향을 줄 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것을 제외한 물품을 의미한다. 또한, 상기 의약외품은 피부외용제 또는 개인위생용품을 포함할 수 있다.As used herein, the term "quasi drug" refers to a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Or non-machinery and the like, or any of the agents used for sterilization, insecticide and similar purposes for the purpose of preventing infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases. Means the goods used are not instruments, machines or devices, and the items used for the purpose of pharmacologically affecting the structure and function of humans or animals except those which are not devices, machines or devices. In addition, the quasi-drug may include external skin preparations or personal hygiene products.
본 발명의 오미자를 함유하는 복합 추출물을 의약외품 첨가물로 사용할 경우, 상기 추출물을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있으며, 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다.When the complex extract containing Schisandra chinensis of the present invention is used as an quasi-drug additive, the extract may be added as it is or used with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method, and the mixed amount of the active ingredient may be used. It may be appropriately determined depending on the purpose.
상기 피부외용제는 특별히 이에 제한되지 않으나, 바람직하게는 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 겔제 또는 젤의 형태로 제조되어 사용될 수 있다. 상기 개인위생용품에는 특별히 이에 제한되지 않으나, 바람직하게는 비누, 화장품, 물티슈, 휴지, 샴푸, 피부 크림, 얼굴 크림, 치약, 립스틱, 향수, 메이크-업, 파운데이션, 볼터치, 마스카라, 아이섀도우, 선스크린 로션, 모발 손질 제품, 에어프레쉬너 겔 또는 세정 겔일 수 있다. 또한, 본 발명의 의약외 품 조성물의 또 다른 예로 소독청결제, 샤워폼, 가그린, 물티슈, 세제비누, 핸드워시, 가습기 충진제, 마스크, 연고제 또는 필터충진제가 있다.The external preparation for skin is not particularly limited thereto, but may be preferably used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel. The personal hygiene products are not particularly limited, but preferably soap, cosmetics, wet wipes, tissue paper, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, make-up, foundation, ball touch, mascara, eye shadow, Sunscreen lotions, hair care products, air freshener gels or cleaning gels. In addition, another example of the quasi-drug composition of the present invention is a disinfectant cleaner, shower foam, gagreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.
본 발명의 또 다른 하나의 양태는 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는, 혈액순환 관련 질환의 예방 또는 개선용 사료첨가제를 제공한다.Another aspect of the present invention provides a feed additive for preventing or improving blood circulation-related diseases, including a complex extract containing Schisandra chinensis as an active ingredient.
본 발명에서 용어, "오미자를 함유하는 복합 추출물", "혈액순환 관련 질환", "예방" 및 "개선"에 대해서는 상기에서 설명한 바와 같다.In the present invention, the terms "complex extract containing Schisandra chinensis", "blood circulation related diseases", "prevention" and "improvement" are as described above.
구체적으로, 본 발명의 오미자를 함유하는 복합 추출물을 혈액순환 관련 질환의 예방 또는 개선을 목적으로 사료첨가제 또는 상기 사료 첨가제를 포함하는 사료용 조성물에 첨가할 수 있다.Specifically, the complex extract containing Schisandra chinensis of the present invention may be added to a feed additive or a feed composition comprising the feed additive for the purpose of preventing or improving blood circulation related diseases.
본 발명에서 용어, "사료첨가제"는 영양소 보충 및 체중감소 예방, 사료 내 섬유소의 소화 이용성 증진, 유질 개선, 번식장애 예방 및 수태율 향상, 하절기 고온 스트레스 예방 등 다양한 효과를 목적으로 사료에 첨가하는 물질을 의미한다. 본 발명의 사료첨가제는 사료관리법상의 보조사료에 해당하며, 탄산수소나트륨, 벤토나이트(bentonite), 산화마그네슘, 복합광물질 등의 광물질제제, 아연, 구리, 코발트, 셀레늄 등의 미량 광물질인 미네랄제제, 케로틴, 비타민 E, 비타민 A, D, E, 니코틴산, 비타민 B 복합체 등의 비타민제, 메티오닌, 리이산 등의 보호아미노산제, 지방산 칼슘염 등의 보호지방산제, 생균제(유산균제), 효모배양물, 곰팡이 발효물 등의 생균, 효모제 등이 추가로 포함될 수 있다.In the present invention, the term "feed additive" is a substance added to the feed for the purpose of various effects, such as supplementation of nutrients and weight loss prevention, improving the digestive availability of the fiber in the feed, improving the quality, prevention of reproduction disorders and improving conception, prevention of high temperature stress in summer Means. The feed additive of the present invention corresponds to a feed supplement under the Feed Control Act, and includes mineral preparations such as sodium bicarbonate, bentonite, magnesium oxide, and composite minerals, mineral preparations such as trace minerals such as zinc, copper, cobalt, and selenium, and keratin. Vitamins such as vitamin E, vitamin A, D, E, nicotinic acid, vitamin B complex, protective amino acids such as methionine, lyric acid, protective fatty acids such as fatty acid calcium salt, probiotics (lactic acid bacteria), yeast culture, mold Probiotics such as fermented products, yeasts and the like may be further included.
본 발명에서 용어, "사료"는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미한다. 구체적으로, 본 발명에 따른 혈액순환 관련 질환의 예방 또는 치료용 조성물을 유효성분으로 포함하는 사료는 당업계의 공지된 다양한 형태의 사료로 제조가능하며, 구체적으로는 농후사료, 조사료 및/또는 특수사료가 포함될 수 있다.As used herein, the term "feed" means any natural or artificial diet, one meal, or the like or any ingredient of the one meal for the animal to eat, ingest, and digest. Specifically, the feed comprising the composition for the prevention or treatment of blood circulation-related diseases according to the present invention as an active ingredient can be prepared in various forms of feed known in the art, specifically thick feed, forage and / or special Feed may be included.
농후사료에는 밀, 귀리, 옥수수 등의 곡류를 포함하는 종자열매류, 곡물을 정제하고 얻는 부산물로서 쌀겨, 밀기울, 보릿겨 등을 포함하는 겨류, 콩, 유체, 깨, 아마인, 코코야자 등을 채유하고 얻는 부산물인 깻묵류와 고구마, 감자 등에서 녹말을 뺀 나머지인 녹말찌꺼기의 주성분인 잔존녹말질류 등의 찌꺼기류, 어분, 물고기찌꺼기, 어류에서 얻은 신선한 액상물을 농축시킨 것인 피시솔루블(fish soluble), 육분(肉粉), 혈분, 우모분, 탈지분유, 우유에서 치즈, 탈지유에서 카제인을 제조할 때의 잔액인 훼이(whey)를 건조한 건조훼이 등의 동물질사료, 효모, 클로렐라, 해조류가 있으나 이에 제한되지 않는다.The rich feed includes seed fruits containing grains such as wheat, oats and corn, and by-products obtained by refining grains, bran, beans, fluids, sesame seeds, linseed, coco, etc., including rice bran, bran and barley bran. Fish soluble, which is a concentrate of fresh liquids obtained from fish residues, fish residues, and fish residues such as by-products such as seaweed, sweet potatoes, and potatoes, which are the remaining components of starch residue. soluble), meat meal, blood meal, milk powder, skim milk powder, milk from cheese, and whey, the balance of manufacturing casein from skim milk, dried foods such as dried whey, yeast, chlorella, and seaweed. This is not restrictive.
조사료에는 야초, 목초, 풋베기 등의 생초(生草)사료, 사료용 순무, 사료용 비트, 순무의 일종인 루터베어거 등의 뿌리채소류, 생초, 풋베기작물, 곡실(穀實) 등을 사일로에 채워 놓고 젖산발효시킨 저장사료인 사일리지(silage), 야초, 목초를 베어 건조시킨 건초, 종축용(種畜用) 작물의 짚, 콩과 식물의 나뭇잎이 있으며, 이에 제한되지 않는다. 특수사료에는 굴껍테기, 암염 등의 미네랄 사료, 요소나 그 유도체인 디우레이드이소부탄 등의 요소사료, 천연사료원료만을 배합했을 때 부족하기 쉬운 성분을 보충하거나, 사료의 저장성을 높이기 위해서 배합사료에 미량으로 첨가하는 물질인 사료첨가물, 식이보조제가 있으나 이에 제한되지 않는다.Forage, raw vegetables such as grasses, grasses, and green grass, fodder turnips, fodder beets, and root vegetables such as Lutherbearger, a type of turnip, raw grass, green grass crops, and grains Silage (silage), grasses, grasses, and dried hay, straws of breeders, and leaves of legumes, which are filled and fermented by lactic acid fermentation, are not limited thereto. Special feeds are supplemented with mineral feeds such as oyster shells and rock salts, urea feeds such as urea and its derivatives, diureide isobutane, and natural feed ingredients. Feed additives and dietary supplements, which are substances added in small amounts, are not limited thereto.
본 발명에 따른 상기 혈액순환 관련 질환의 예방 또는 치료용 조성물을 포함하는 사료용 조성물은 당업계에 공지된 다양한 사료제조방법에 따라 적절한 유효 농도 범위에서 오미자를 함유하는 복합 추출물을 첨가하여 제조 가능하다.Feed composition comprising the composition for the prevention or treatment of blood circulation-related diseases according to the present invention can be prepared by adding a complex extract containing Schisandra chinensis in a suitable effective concentration range according to various feed production methods known in the art.
본 발명에 따른 사료용 조성물은 혈액순환 관련 질환의 예방 또는 치료를 목적으로 하는 개체이면 특별히 한정되지 않고, 어떠한 것이든 적용가능하다. 예를 들면, 원숭이, 개, 고양이, 토끼, 모르모트, 랫트, 마우스, 소, 양, 돼지, 염소 등과 같은 비인간동물, 조류 및 어류 등이 있으나, 이에 한정된 것은 아니며, 어느 개체에도 적용이 가능하다.Feed composition according to the present invention is not particularly limited as long as it is an object for the purpose of preventing or treating blood circulation-related diseases, any one can be applied. For example, monkeys, dogs, cats, rabbits, morphotes, rats, mice, cows, sheep, pigs, goats and the like, but not limited to, such as, but not limited to, and can be applied to any individual.
본 발명의 또 다른 하나의 양태는 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.Another embodiment of the present invention provides a health functional food composition for preventing or improving blood circulation related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
구체적으로는, 오미자를 함유하는 복합 추출물은 비만, 고지혈증, 고혈압, 동맥경화, 고인슐린 혈증, 당뇨병, 간질환 등의 혈액순환 관련 질환의 예방 또는 개선을 목적으로 건강기능식품 조성물에 첨가될 수 있다. Specifically, the complex extract containing Schisandra chinensis may be added to the dietary supplement composition for the purpose of preventing or improving blood circulation related diseases such as obesity, hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, diabetes, liver disease, and the like. .
상기 건강기능식품 조성물은 식품학적으로 허용가능한 담체를 포함할 수 있다.The dietary supplement composition may include a food acceptable carrier.
본 발명의 식품 조성물은 기능성 식품(functional food), 영양 보조제(nutritional supplement), 건강 식품(health food) 및 식품 첨가제(food additives)등의 모든 형태를 포함하여, 상기 유형의 식품 조성물은 당업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다.Food compositions of the present invention include all forms of functional foods, nutritional supplements, health foods and food additives, and the like. It may be prepared in various forms according to known conventional methods.
오미자를 함유하는 복합 추출물을 식품 첨가물로 사용할 경우, 오미자를 함유하는 복합 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 오미자를 함유하는 복합 추출물은 원료 조성물 중 0.0001~1 중량%, 바람직하게는 0.001~0.1중량%의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하로도 사용될 수 있다.When a complex extract containing Schisandra chinensis is used as a food additive, the complex extract containing Schisandra chinensis can be added as it is or used together with other food or food ingredients, and can be suitably used according to a conventional method. The mixed amount of the active ingredient can be determined suitably according to the purpose of use (prevention, health or therapeutic treatment). In general, the composite extract containing Schisandra chinensis in the preparation of food or beverage is added in an amount of 0.0001 to 1% by weight, preferably 0.001 to 0.1% by weight in the raw material composition. However, in the case of prolonged ingestion for health and hygiene purposes or for health control purposes, the amount may be used below the above range.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는, 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함할 수 있다.There is no particular limitation on the kind of food. Examples of foods to which the above substances can be added include dairy products including meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, beverages, teas and drinks. , Alcoholic beverages and vitamin complexes, and the like, may include all of the health food in the conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 당 일반적으로 약 0.01~0.04 g, 구체적으로는 약 0.02~0.03 g이 사용될 수 있다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 compositions of the present invention can be used.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01~0.1 중량부의 범위에서 선택되는 것이 일반적이다. 그밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 과육의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01~10 중량부의 범위에서 선택되는 것이 일반적이며, 이들 성분들은 독립적으로 또는 조합하여 사용할 수 있다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. Although the proportion of such pulp is not critical, it is generally selected from the range of 0.01 to 10 parts by weight per 100 parts by weight of the composition of the present invention, these components can be used independently or in combination.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention more specifically, but the scope of the present invention is not limited by these examples.
실시예 1: 오미자를 함유하는 복합 추출물의 제조Example 1: Preparation of Complex Extract Containing Schizandra chinensis
1-1. 오미자-강황 복합 추출물의 제조1-1. Preparation of Schizandra chinensis Extract
문경산 건오미자(1kg) 및 건조된 강황(1kg)을 각각 15L의 70% 에탄올(EtOH)을 사용하여 80℃에서 3시간 환류추출한 후 여과한 액을 50℃에서 감압 농축하였다. 상기 농축액을 각각 동결건조하여 오미자 추출물(340g) 및 강황 추출물(63g)을 제조하였다.Mungyeong acid Schisandra chinensis (1 kg) and dried turmeric (1 kg) were respectively refluxed at 80 ° C. for 3 hours using 15 L of 70% ethanol (EtOH), and the filtrate was concentrated under reduced pressure at 50 ° C. The concentrate was lyophilized to prepare Schizandra chinensis extract (340 g) and Turmeric extract (63 g).
또한, 상기 제조된 각각의 오미자 추출물 및 강황 추출물을 무게 비율로 혼합하여 오미자와 강황의 비가 각각 4:1, 2:1, 1:1, 1:2 및 1:4인 복합 추출물을 제조하였다. In addition, each of the prepared Schisandra chinensis extract and turmeric extract were mixed in a weight ratio to prepare a complex extract having a ratio of Schisandra chinensis and 4: 1, 2: 1, 1: 1, 1: 2 and 1: 4, respectively.
1-2. 오미자-상엽 복합 추출물의 제조1-2. Preparation of Schizandra chinensis Combined Extract
문경산 건오미자(1kg) 및 건조된 상엽(1kg)을 각각 15L의 70% 에탄올(EtOH)을 사용하여 80℃에서 3시간 환류추출한 후 여과한 액을 50℃에서 감압 농축하였다. 상기 농축액을 각각 동결건조하여 오미자 추출물(340g) 및 상엽 추출물(179g)을 제조하였다.Mungyeong acid Schisandra chinensis (1 kg) and dried upper leaves (1 kg) were respectively refluxed at 80 ° C. for 3 hours using 15 L of 70% ethanol (EtOH), and the filtrate was concentrated under reduced pressure at 50 ° C. Each of the concentrates was lyophilized to prepare Schizandra chinensis extract (340 g) and upper leaf extract (179 g).
또한, 상기 제조된 각각의 오미자 추출물 및 상엽 추출물을 무게 비율로 혼합하여 오미자와 상엽의 비가 각각 4:1, 2:1, 1:1, 1:2 및 1:4인 복합 추출물을 제조하였다. In addition, each of the Schisandra chinensis extract and the upper leaf extract was mixed in a weight ratio to prepare a complex extract having a ratio of Schisandra chinensis and the upper leaf 4: 1, 2: 1, 1: 1, 1: 2 and 1: 4, respectively.
실시예 2: 카라기난(carageenan) 유도 혈전 동물모델에서 오미자 함유 복합 추출물들의 혈전억제 효능 평가 Example 2: Evaluation of the Thrombotic Inhibitory Effect of Schisandra chinensis Extracts in Carageenan-induced Thrombus Animal Model
2-1: 오미자-강황 복합 추출물의 혈전억제 효능 평가2-1: Evaluation of Thrombus Inhibitory Effect of Schisandra chinensis Extract
8주령 ICR 생쥐(mice)에 1%의 카라기난(carrageenan)(type I)을 생리식염수에 녹인 후, 약 40 ㎕를 생쥐 오른쪽 뒷다리 발가락 사이에 주사하고, 24시간, 48시간, 72시간이 지난 후 꼬리 혈전 형성길이(tail thrombosis)를 디지털 버니어 캘리퍼스(Mitutoyo, japan)로 측정하였다.After dissolving 1% carrageenan (type I) in physiological saline in 8-week-old ICR mice, approximately 40 μl was injected between the right hind toes of the mouse and after 24 hours, 48 hours, and 72 hours. Tail thrombosis was measured with a digital vernier caliper (Mitutoyo, Japan).
상기 실시예 1-1에서 제조한 오미자-강황 복합 추출물 200mg/kg을 오미자 및 강황의 비율을 달리하여 카라기난 주사 3일전부터 매일 경구투여하고, 혈전 유도 당일에는 카라기난 주사 1시간 전에 경구투여하였으며, 그 이후에는 카라기난 주사 후 23시간, 47시간, 또는 71시간째에 경구투여하였다.200 mg / kg of Schisandra chinensis extract prepared in Example 1-1 was orally administered every 3 days before carrageenan injection with different ratios of Schisandra chinensis and turmeric, and orally administered 1 hour before carrageenan injection on the day of thrombus induction. Thereafter, oral administration was performed at 23 hours, 47 hours, or 71 hours after carrageenan injection.
카라기난 주사 후 72시간이 지난 후의 꼬리 혈전 형성길이를 측정하여 도 1에 나타내었다.The tail thrombus formation length after 72 hours after carrageenan injection was measured and shown in FIG. 1.
도 1에서 볼 수 있는 바와 같이, 카라기난 만을 랫트에 주사한 후 72시간째에 관찰한 꼬리 혈전 생성길이는 평균 2.85cm이었으나, 오미자를 함유하는 복합 추출물을 주사한 경우에는 그 억제율이 각각 4:1인 경우 52%, 2:1인 경우 47%, 1:1인 경우 77%, 및 1:2인 경우 63%로 꼬리 혈전 생성길이가 그보다 훨씬 짧았으며, 특히, 오미자:강황의 비율이 1:1인 복합 추출물의 경우 평균 약 1.10cm로(p<0.01), 가장 우수한 혈전 억제 효과를 가지고 있음을 확인할 수 있었다. 이로써, 오미자를 함유하는 복합 추출물이 매우 우수한 혈전 생성 억제능을 가지고 있음을 알 수 있으며, 특히, 오미자-강황 복합 추출물의 경우 비율이 1:1인 경우가 가장 우수한 혈전 생성 억제능을 가짐을 알 수 있었다. As shown in FIG. 1, the tail thrombus formation length observed at 72 hours after the injection of only carrageenan into rats was 2.85 cm on average, but when the complex extract containing Schisandra chinensis was injected, the inhibition rate was 4: 1. 52%, 47% for 2: 1, 77% for 1: 1, and 63% for 1: 2, the tail blood clot length was much shorter. In the case of the composite extract of 1 person averaged about 1.10cm (p <0.01), it was confirmed that it has the best thrombus inhibitory effect. As a result, it can be seen that the complex extract containing Schisandra chinensis has a very good antithrombotic activity, and in particular, the ratio of Schisandra chinensis extract has the most excellent antithrombotic activity. .
2-2: 오미자-상엽 복합 추출물의 혈전억제 효능 평가2-2: Evaluation of Thrombus Inhibitory Efficacy of Schisandra chinensis L. Extract
8주령 ICR 생쥐(mice)에 1%의 카라기난(carrageenan)(type I)을 생리식염수에 녹인 후, 약 40 ㎕를 생쥐 오른쪽 뒷다리 발가락 사이에 주사하고, 24시간, 48시간, 72시간이 지난 후 꼬리 혈전 형성길이(tail thrombosis)를 디지털 버니어 캘리퍼스(Mitutoyo, japan)로 측정하였다.After dissolving 1% carrageenan (type I) in physiological saline in 8-week-old ICR mice, approximately 40 μl was injected between the right hind toes of the mouse and after 24 hours, 48 hours, and 72 hours. Tail thrombosis was measured with a digital vernier caliper (Mitutoyo, Japan).
상기 실시예 1-2에서 제조한 오미자-상엽 복합 추출물 200mg/kg을 오미자와 상엽의 비율을 달리하여 카라기난 주사 3일전부터 매일 경구투여하고, 혈전 유도 당일에는 카라기난 주사 1시간 전에 경구투여하였으며, 그 이후에는 카라기난 주사 후 23시간, 47시간, 71시간째에 경구 투여하였다. 카라기난 주사 후 72시간이 지난 후의 꼬리 혈전 형성길이를 측정하여 도 2에 나타내었다(도 2).200 mg / kg of Schisandra chinensis composite extract prepared in Example 1-2 was orally administered every 3 days before carrageenan injection with different ratios of Schizandra chinensis and orally administered 1 hour before carrageenan injection on the day of thrombus induction. Thereafter, oral administration was performed at 23 hours, 47 hours, and 71 hours after carrageenan injection. The tail thrombus formation length after 72 hours after carrageenan injection was measured and shown in FIG. 2 (FIG. 2).
도 2에서 볼 수 있는 바와 같이, 카라기난 만을 랫트에 주사한 후 72시간째에 관찰한 꼬리 혈전 생성길이는 평균 2.73cm이었으나, 오미자를 함유하는 복합 추출물을 주사한 경우에는 그 억제율이 4:1인 경우 39%, 2:1인 경우 37%, 1:1인 경우 69%, 1:2인 경우 72%, 1:4인 경우 53%로, 꼬리 혈전 생성길이가 그보다 훨씬 짧았으며, 특히, 오미자:강황의 비율이 1:2인 복합 추출물의 경우 꼬리 혈전 생성길이의 평균값이 평균 약 1.06cm로(p<0.001), 가장 우수한 혈전 억제능을 가지고 있음을 확인할 수 있었다. 이로써, 오미자를 함유하는 복합 추출물이 매우 우수한 혈전 생성 억제능을 가지고 있음을 알 수 있으며, 특히, 오미자-상엽 복합 추출물이 매우 우수한 혈전 생성 억제능을 가짐을 알 수 있었다. As can be seen in Figure 2, 72 hours after the injection of carrageenan in rats, the average tail thrombus generation length was 2.73 cm, but when injected with a complex extract containing Schisandra chinensis inhibition rate is 4: 1 39% of cases, 37% of cases of 2: 1, 69% of cases of 1: 1, 72% of cases of 1: 2, 53% of cases of 1: 4, and the length of tail blood clots was much shorter. In the case of the 1: 2 complex extract of turmeric, the average value of tail thrombus generation length was about 1.06 cm (p <0.001), indicating that it had the best thrombus inhibitory ability. Thus, it can be seen that the complex extract containing Schisandra chinensis has a very good antithrombotic activity, and in particular, the Schisandra chinensis extract has a very good antithrombotic activity.
2-3: 오미자, 강황 단독 추출물의 혈전억제 효능 평가 및 복합 추출물의 상승 효과 분석
2-3: Evaluation of the thrombus inhibitory effect of Schizandra chinensis and Turmeric extract
본원발명의 오미자를 함유하는 복합 추출물, 구체적으로는 오미자-강황 복합 추출물이 오미자 또는 강황 단독 추출물보다 우수한 효과를 가지고 있음을 확인하기 위하여 실시예 2-1과 동일한 실험을 오미자 또는 강황 단독 추출물에 대해 실시한 후 복합 추출물의 효과와 비교해보았다. 또한, 오미자-강황 복합 추출물의 농도에 따른 효과를 확인해 보기 위하여, 실시예 2-1에서 실험한 농도(200mg/kg)보다 낮은 농도(100mg/kg)에서도 실험하여 농도에 따른 효과를 확인하였으며, 그 결과는 도 3에 도시한 바와 같다. In order to confirm that the complex extract containing Schisandra chinensis of the present invention, specifically, Schisandra chinensis extract has a superior effect than Schisandra chinensis or Turmeric alone extract, the same experiment as in Example 2-1 was performed on Schisandra chinensis or Turmeric alone extract. Compared with the effect of the composite extract after the implementation. In addition, in order to check the effect according to the concentration of the extract of Schizandra chinensis extract, the effect according to the concentration was confirmed by experimenting at a concentration (100mg / kg) lower than the concentration (200mg / kg) tested in Example 2-1, The result is as shown in FIG.
그 결과, 도 3에서 알 수 있는 바와 같이, 오미자 및 강황 단독 추출물 각각의 꼬리 혈전 생성 억제율은 각각 36% 및 21%였으나, 오미자-강황 복합 추출물 100mg/kg의 경우에는 억제율이 45%이었으며, 특히, 실시예 2-1과 동일한 조건에서 실험한 오미자-강황 복합 추출물 200mg/kg의 억제율은 84%로 나타나, 양성 대조군으로 사용된 ASA 및 Ticlopidine의 억제율에 거의 필적하는 효과를 가짐을 알 수 있었다. As a result, as can be seen in Figure 3, the inhibition of tail thrombus formation of Schizandra chinensis and Turmeric alone extract was 36% and 21%, respectively, but the inhibition rate was 45% for Schisandra chinensis-complex extract 100mg / kg. Inhibitory rate of 200 mg / kg of Schisandra chinensis extract extracted in the same conditions as in Example 2-1 was 84%, indicating that the ASA and Ticlopidine used as a positive control almost comparable to the inhibition rate.
특히, 오미자-강황 복합 추출물이 각각의 단독 추출물보다 상승 효과를 가지는지를 확인해 보기 위하여 콜비식으로 계산해 본 결과, 각각의 억제율인 36%, 및 21%를 이용하여 계산한 콜비식 E의 값은 49%((36+21)-(36x21/100))인데 반해, 오미자-강황 복합 추출물의 실제 억제율은 84%라는 점에서, 본 발명의 오미자-강황 복합 추출물은 단독 추출물이 가지고 있는 효과보다 훨씬 큰 상승 효과를 나타냄을 알 수 있었다. In particular, as a result of calculating Colby's formula to confirm whether the Schisandra chinensis extract has a synergistic effect than each single extract, Colby's E value calculated using 36% and 21% of inhibition rate is 49 In contrast to% ((36 + 21)-(36x21 / 100)), the actual inhibition rate of the Schisandra chinensis extract is 84%, so the Schisandra chinensis extract of the present invention is much larger than the effect of the extract alone. It can be seen that there is a synergistic effect.
2-4: 오미자, 상엽 단독 추출물의 혈전억제 효능 평가 및 복합 추출물의 상승 효과 분석 2-4: Evaluation of the thrombus inhibitory effect of Schisandra chinensis and Upper lobe extract and analysis of synergistic effect
본원발명의 오미자를 함유하는 복합 추출물, 구체적으로는, 오미자-상엽 복합 추출물이 오미자 또는 상엽 단독 추출물보다 우수한 효과를 가지고 있음을 확인하기 위하여 실시예 2-2와 동일한 실험을 오미자 또는 상엽 단독 추출물에 대해서도 실시한 후 복합 추출물의 효과와 비교해 보았다. 또한, 오미자-상엽 복합 추출물의 농도에 따른 효과를 확인해 보기 위하여, 실시예 2-2에서 실험한 농도 200mg/kg보다 낮은 농도 100mg/kg에서도 실험하여 농도에 따른 효과를 확인하였으며, 그 결과는 도 4에 도시한 바와 같다. In order to confirm that the complex extract containing Schisandra chinensis of the present invention, specifically, Schisandra chinensis extract, has the superior effect than Schisandra chinensis or the extract of Schisandra chinensis alone, the same experiment as in Example 2-2 was performed on Schisandra chinensis or Lettuce melon extract. After performing also compared with the effect of the composite extract. In addition, in order to check the effect of the concentration of Schisandra chinensis extract, the effect of the concentration was confirmed by experimenting at a concentration of 100 mg / kg lower than the concentration of 200 mg / kg tested in Example 2-2, the result is As shown in 4.
그 결과 도 4에서 알 수 있는 바와 같이, 오미자 및 상엽 단독 추출물 각각의 꼬리 혈전 생성 억제율은 각각 36% 및 41%였으나, 오미자-상엽 복합 추출물 100mg/kg의 경우에는 억제율이 46%로 나타났으며, 실시예 2-2와 동일한 조건에서 실험한 오미자-강황 복합 추출물 200mg/kg의 억제율은 92%로 나타나, 양성 대조군으로 사용된 ASA 및 Ticlopidine의 억제율을 능가하는 혈전 생성 억제능을 가짐을 알 수 있었다.As can be seen in Figure 4, the inhibition of tail thrombus formation of Schizandra chinensis and Upper lobe extracts was 36% and 41%, respectively, but the inhibition rate was 46% for Schisandra chinensis extract 100mg / kg. Inhibitory rate of 200 mg / kg of Schisandra chinensis extract tested in the same conditions as in Example 2-2 was 92%, indicating that the inhibitory activity of thrombus formation was superior to that of ASA and Ticlopidine used as a positive control. .
특히, 오미자-상엽 복합 추출물이 각각의 단독 추출물보다 상승 효과를 가지는지를 확인해 보기 위하여, 콜비식으로 계산해 본 결과, 각각의 억제율인 36% 및 41%를 이용하여 계산한 콜비식 E의 값은 62%((36+41)-(36x41/100))인데 반해, 오미자-상엽 복합 추출물의 실제 억제율은 92%라는 점에서, 본 발명의 오미자-상엽 복합 추출물은 단독 추출물이 가지고 있는 효과보다 훨씬 큰 상승 효과를 나타냄을 알 수 있었다.In particular, in order to check whether the Schisandra chinensis extract has a synergistic effect than the single extract alone, as a result of calculating Colby's formula, the value of Colby's Formula E calculated using 36% and 41% of inhibition rate is 62, respectively. In contrast to% ((36 + 41)-(36x41 / 100)), the actual inhibition rate of the Schisandra chinensis extract is 92%, and the Schisandra chinensis extract of the present invention is much larger than the effect of the extract alone. It can be seen that there is a synergistic effect.
실시예 3: 오미자 함유 복합 추출물들의 ex-vivo 혈소판 응집 억제 효과Example 3: Ex-vivo Platelet Aggregation Inhibitory Effect of Schisandra chinensis Extracts
3-1: 오미자-강황 복합 추출물의 혈소판 응집 억제 효과3-1: Antiplatelet Aggregation Inhibitory Effect of Schizandra chinensis Extract
오미자-강황 복합 추출물의 ex-vivo 혈소판 응집 억제 효과를 확인하고자 실시 예 2-2에서 꼬리의 혈전길이를 측정 한 SD rat를 마취한 후, 복강 안쪽에 있는 동맥 혈액을 천천히 채혈하여 3.2% 쇼듐시트레이트 항응고제가 들어 있는 튜브에 혈액을 담은 후, 채혈한 혈액을 1,000 rpm에서 10분 동안 원심분리 하였다. 분리된 혈소판 풍부혈장(platelet rich plasma, PRP)은 다시 3,000 rpm에서 10분 동안 원심분리 하여 얻은 무혈소판혈장(platelet poor plasma)으로 희석하여 혈소판 수 4.0×108를 기준으로 사용하였다. In order to confirm the ex-vivo platelet aggregation inhibitory effect of the extract of Schisandra chinensis, anesthesia was measured in Example 2-2, and anesthetized the SD rat, and then blood was slowly collected from the arterial blood in the abdominal cavity to obtain 3.2% sodium sheet. After immersing the blood in the tube containing the rate anticoagulant, the collected blood was centrifuged at 1,000 rpm for 10 minutes. Isolated platelet rich plasma (PRP) was diluted with platelet poor plasma obtained by centrifugation at 3,000 rpm for 10 minutes, and then used as a platelet count of 4.0 × 10 8 .
혈소판 응집 억제 활성은 PRP를 통해 혈소판 응집을 확인하는 빛을 이용한(optical) 방법으로, 혈소판의 응집에 따른 전기저항 변화와 광원의 변화를 측정하였다. 혈액 245 ㎕를 큐벳(cuvette)에 넣고 혈소판 응집기 700-2 (Chrono-Log. Havertown, PA)를 사용하여 37℃에서 10분 동안 반응시킨 후, 오미자와 강황의 비율을 달리한 오미자-강황 복합 추출물 시료들을 각각 2.5 ㎕ 가하여 반응시켰다. 그 후, 일정시간 간격으로 베이스라인(baseline)을 확인한 후, 혈소판 응집 촉진물질인 콜라겐 10 ㎍/㎖을 넣어 1,200 rpm으로 교반하면서 37℃에서 최대 10분 동안 측정하였다.The platelet aggregation inhibitory activity is an optical method for confirming platelet aggregation through PRP, and the change of the electrical resistance and the light source according to the aggregation of platelets was measured. 245 μl of blood was put in a cuvette and reacted for 10 minutes at 37 ° C. using a platelet agglomerate 700-2 (Chrono-Log.Havertown, PA). 2.5 μl of extract samples were added to each sample for reaction. Then, after confirming the baseline (baseline) at regular intervals, 10 ㎍ / ㎖ of collagen, which is a platelet aggregation promoter, was added and measured at 37 ° C. for up to 10 minutes while stirring at 1,200 rpm.
그 결과 도 5에서 알 수 있는 바와 같이, 혈소판과 콜라겐만을 반응시켰을 때의 혈소판의 응집율이 100인 것을 대조군으로 하여 비교해보면, 오미자를 함유하는 복합 추출물, 특히, 오미자-강황의 복합 추출물의 경우 80.94 내지 92.44의 범위로 나타나는 것을 확인함으로써, 본 발명의 복합 추출물 모두 대조군 대비 우수한 혈소판 응집 억제능을 가짐을 알 수 있었다(도 5). As a result, as can be seen in Figure 5, when comparing the platelet aggregation rate when the reaction of only platelets and collagen is 100 as a control, a complex extract containing Schisandra chinensis, especially in the case of a complex extract of Schisandra chinensis By confirming that it appears in the range of 80.94 to 92.44, it can be seen that the complex extract of the present invention all have excellent platelet aggregation inhibitory ability compared to the control (FIG. 5).
3-2: 오미자-상엽 복합 추출물의 혈소판 응집 억제 효과3-2: Platelet Aggregation Inhibitory Effect of Schizandrae Fructus Extract
오미자-상엽 복합 추출물의 ex-vivo 혈소판 응집 억제 효과를 확인하고자 실시 예 2-3에서 꼬리의 혈전길이를 측정 한 SD rat를 마취한 다음 복강 안쪽에 있는 동맥 혈액을 천천히 채혈하여 3.2% 쇼듐시트레이트 항응고제가 들어 있는 튜브에 혈액을 담았다. 채혈한 혈액을 1,000 rpm에서 10분 동안 원심분리 하였다. 분리된 혈소판 풍부혈장(platelet rich plasma, PRP)은 다시 3,000 rpm에서 10분 동안 원심분리 하여 얻은 무혈소판혈장(platelet poor plasma)으로 희석하여 혈소판 수 4.0×108를 기준으로 사용하였다. In order to confirm the ex-vivo platelet aggregation inhibitory effect of the extract of Schisandra chinensis Fructus, anesthesia was measured in Example 2-3. Blood was placed in a tube containing anticoagulant. The collected blood was centrifuged at 1,000 rpm for 10 minutes. Isolated platelet rich plasma (PRP) was diluted with platelet poor plasma obtained by centrifugation at 3,000 rpm for 10 minutes, and then used as a platelet count of 4.0 × 10 8 .
혈소판 응집 억제 활성은 PRP를 통해 혈소판 응집을 확인하는 빛을 이용한(optical) 방법으로, 혈소판의 응집에 따른 전기저항 변화와 광원의 변화를 측정하였다. 혈액 245 ㎕를 큐벳(cuvette)에 넣고 혈소판 응집기 700-2 (Chrono-Log. Havertown, PA)를 사용하여 37℃에서 10분 동안 반응시킨 후, 오미자와 상엽의 비율을 달리한 오미자-상엽 복합 추출물 시료들을 각각 2.5 ㎕ 가하여 반응시켰다. 그 후, 일정시간 간격으로 베이스라인(baseline)을 확인한 후, 혈소판 응집 촉진물질인 콜라겐 10 ㎍/㎖을 넣어 1,200 rpm으로 교반하면서 37℃에서 최대 10분 동안 측정하였다.The platelet aggregation inhibitory activity is an optical method for confirming platelet aggregation through PRP, and the change of the electrical resistance and the light source according to the aggregation of platelets was measured. 245 μl of blood was put in a cuvette and reacted at 37 ° C. for 10 minutes using a platelet aggregator 700-2 (Chrono-Log.Havertown, PA). 2.5 μl of extract samples were added to each sample for reaction. Then, after confirming the baseline (baseline) at regular intervals, 10 ㎍ / ㎖ of collagen, which is a platelet aggregation promoter, was added and measured at 37 ° C. for up to 10 minutes while stirring at 1,200 rpm.
그 결과 도 6에서 알 수 있는 바와 같이, 혈소판과 콜라겐만을 반응시켰을 때의 혈소판의 응집율이 100인 것을 대조군으로 하여 비교해보면, 오미자를 함유하는 복합 추출물, 특히, 오미자-상엽의 복합 추출물의 경우 86.85 내지 97.65 의 범위로 나타나는 것을 확인함으로써, 본 발명의 복합 추출물 모두 대조군 대비 우수한 혈소판 응집 억제능을 가짐을 알 수 있었다. As a result, as can be seen in Figure 6, when comparing the platelet aggregation rate when the reaction of only platelets and collagen is 100 as a control, in the case of a complex extract containing Schisandra chinensis, in particular, a complex extract of Schisandra chinensis By confirming that it appears in the range of 86.85 to 97.65, it can be seen that the composite extract of the present invention all have excellent platelet aggregation inhibitory ability compared to the control.
실시예 4: 공지된 오미자 함유 19종 복합 추출물과의 혈액순환 관련 질환에 대한 효과 비교Example 4 Comparison of Effects on Blood Circulation-Related Diseases with 19 Known Schisandra chinensis Extracts
4-1: 혈전 생성 억제능 비교4-1: Comparison of thrombus generation inhibitory ability
본 발명의 오미자 함유 복합 추출물이 공지의 복합 추출물보다 혈액 순환 관련 질환에 대하여 우수한 치료 효과를 가지는지를 확인해 보기 위하여, 본 발명의 오미자 함유 복합 추출물과 오미자, 강황, 상엽 등을 포함하는 공지의 오미자 함유 19종 복합 추출물(대한민국 특허 제2012-0095504호, 이하 ‘공지의 복합물’이라 함)의 혈전 생성 억제능을 구체적으로 비교하여 보았다. 상기 공지의 복합물은 오미자, 메밀, 보리, 생지황, 비름나물, 쥐눈이콩, 돼지감자, 팥, 홍개, 강황, 뽕잎, 진피, 구절초, 차가버섯, 오가피, 하수오, 대추, 문어, 도토리로 이루어진 복합 추출물로, 혈액 내 콜레스테롤을 억제하고 혈관 정화 기능을 가진다고 알려진 복합 추출물이다.In order to check whether the extract of Schisandra chinensis-containing complex of the present invention has a superior therapeutic effect on blood circulation-related diseases than the known complex extract, the Schisandra chinensis containing extract of the present invention and Schisandra chinensis containing turmeric, turmeric, upper leaf, etc. Inhibition of thrombus formation of 19 complex extracts (Korean Patent No. 2012-0095504, hereinafter known as 'composite complex') was compared in detail. The well-known complex is Schisandra chinensis, buckwheat, barley, raw yellow sulfur, aquatic herb, rat eye bean, pork potato, red bean, red dog, turmeric, mulberry leaf, dermis, gujeolcho, chaga, ogapi, sewage, jujube, octopus, acorn It is a complex extract known to inhibit blood cholesterol and have blood vessel purification functions.
상기 실시예 2와 동일한 방법으로 카라기난(carageenan) 유도 혈전 동물모델을 이용하여 상기 공지의 복합물(200mg/kg, 400mg/kg)의 혈전 생성 억제능을 실험한 후, 그 결과를 도 7에 나타내었다.In the same manner as in Example 2, using the carrageenan-induced thrombus animal model was tested for the thrombus generation inhibitory ability of the known complex (200mg / kg, 400mg / kg), the results are shown in FIG.
도 7에서 알 수 있는 바와 같이, 공지의 복합물은 카라기난만 주사한 경우의 혈전 생성 길이와 큰 차이가 없어 혈전 생성 억제능이 거의 없음을 알 수 있었다. 반면, 본 발명의 오미자-강황(1:1) 복합 추출물 및 오미자-상엽(1:2) 복합 추출물의 경우에는 실시예 2를 통해 확인한 바와 같이, 꼬리 혈전 생성 길이 평균값이 각각 1.10cm 및 1.06cm으로 카라기난만 주사한 경우보다 혈전 생성 억제능이 매우 우수하게 나타나 상기 공지의 복합물과 비교할 때, 현저히 우수한 혈전 생성 억제능을 가짐을 확인할 수 있었다. As can be seen in FIG. 7, the known complex has almost no difference from the thrombus generation length when only carrageenan is injected, and thus, it has been found that there is almost no inhibition of thrombus generation. On the other hand, in the case of Schisandra chinensis (1: 1) complex extract and Schisandra chinensis (1: 2) complex extract of the present invention, as shown in Example 2, the average value of tail thrombus generation length was 1.10 cm and 1.06 cm, respectively. As a result, the antithrombotic activity was significantly higher than that of only carrageenan injection, and it was confirmed that the antithrombotic activity was significantly superior to that of the known complex.
4-2: 혈소판 응집 억제 효과 비교4-2: Comparison of Platelet Aggregation Inhibitory Effect
본 발명의 오미자 함유 복합 추출물이 공지의 복합물보다 혈액 순환 관련 질환에 대하여 우수한 치료 효과를 가지는지를 확인해 보기 위하여, 본 발명의 오미자 함유 복합 추출물과 공지의 복합물을 실시예 3의 방법과 같은 방법으로 실험하여 혈소판 응집 억제 효과를 비교해보았다. 구체적으로, 공지의 복합물은 200mg/kg 및 400mg/kg의 2가지 농도로 나누어 실험하였으며, 양성 대조군으로는 아스피린(25mg/kg)을, 혈소판 응집 자극 물질로는 콜라겐(10㎍/ml)을 사용하였다. 그 결과는 하기 도 8에 나타낸 바와 같다.In order to confirm whether the Schizandra chinensis extract of the present invention has a superior therapeutic effect against blood circulation-related diseases than the well-known complex, the Schizandra chinensis-containing extract of the present invention and the well-known complex were tested in the same manner as in Example 3 To compare the effect of inhibiting platelet aggregation. Specifically, the known complex was tested in two concentrations of 200 mg / kg and 400 mg / kg, using aspirin (25 mg / kg) as a positive control and collagen (10 µg / ml) as a platelet aggregation stimulating substance. It was. The result is as shown in FIG.
도 8에서 알 수 있는 바와 같이, 공지의 복합물은 콜라겐으로 혈소판이 응집된 경우를 100%로 할 때 오미자-강황 및 오미자-상엽 복합물은 200 mg/kg 저용량에서 88.8% 및 86.8%로 통계적 유의성을 가지고 감소한 반면, 공지의 복합물(선행기술)은 200 mg/kg 용량에서 105.8% 나타내어 혈소판 응집 억제 효과를 가지지 않았으며 400 mg/kg의 고용량에서도 92.5%의 약한 억제 효과를 나타내어 별다른 혈소판 응집 억제 효과를 가지지 않음을 알 수 있었는바, 공지의 복합물은 오미자에 강황과 상엽 외에도 17종의 기타 활성 성분으로 모두 포함하고 있음에도 불구하고 본 발명의 추출물보다 그 효과가 유의미하게 낮음을 알 수 있었다. As can be seen in FIG. 8, the known complexes have a statistical significance of 88.8% and 86.8% at the 200 mg / kg low dose when the S. aureus-S. Turmeric and S. aureus complexes are 100% when platelets are aggregated with collagen. On the other hand, the known complex (prior art) showed 105.8% at the 200 mg / kg dose, which did not have a platelet aggregation inhibitory effect, and a high inhibitory effect of 92.5% at a high dose of 400 mg / kg. It can be seen that it does not have a known complex, although it contains all 17 other active ingredients in addition to turmeric and lettuce in Schizandra chinensis, the effect was significantly lower than the extract of the present invention.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art will appreciate that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.
Claims (14)
- 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 치료용 약학 조성물.A pharmaceutical composition for preventing or treating blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- 제1항에 있어서, 상기 복합 추출물은 오미자; 및 강황 또는 상엽 추출물인 것인, 약학 조성물.According to claim 1, wherein the complex extract Schisandra chinensis; And turmeric or upper leaf extract.
- 제2항에 있어서, 상기 복합 추출물은 오미자 및 강황을 0.25 내지 4 : 1의 중량비로 포함하는 것인, 약학 조성물.The pharmaceutical composition of claim 2, wherein the complex extract comprises Schisandra chinensis and turmeric in a weight ratio of 0.25 to 4: 1.
- 제2항에 있어서, 상기 복합 추출물은 오미자 및 상엽을 0.25 내지 4 : 1의 중량비로 포함하는 것인, 약학 조성물.The pharmaceutical composition of claim 2, wherein the complex extract comprises Schisandra chinensis and the upper lobe in a weight ratio of 0.25 to 4: 1.
- 제1항에 있어서, 상기 추출물은 물, 탄소수 1 내지 4의 알콜 및 이들의 혼합 용매로 구성되는 군으로부터 선택되는 용매로 추출한 것인, 약학 조성물.The pharmaceutical composition of claim 1, wherein the extract is extracted with a solvent selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof.
- 제1항에 있어서, 상기 약학 조성물은 약제학적으로 허용 가능한 담체를 추가로 포함하는 것인, 약학 조성물.The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
- 제1항에 있어서, 상기 혈액순환 관련 질환은 고지혈증, 고혈압, 동맥경화, 심근경색, 뇌졸중 및 뇌경색으로 이루어진 군에서 선택된 하나 이상의 질환인 것인, 약학 조성물.The pharmaceutical composition of claim 1, wherein the blood circulation related disease is one or more diseases selected from the group consisting of hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke, and cerebral infarction.
- 제1항에 있어서, 상기 약학 조성물은 혈전 생성을 억제하는 것인, 약학 조성물.The pharmaceutical composition of claim 1, wherein the pharmaceutical composition inhibits blood clot production.
- 제1항에 있어서, 상기 약학 조성물은 혈소판 응집을 억제하는 것인, 약학 조성물.The pharmaceutical composition of claim 1, wherein the pharmaceutical composition inhibits platelet aggregation.
- 제1항 내지 제9항 중 어느 한 항의 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는, 혈액순환 관련 질환 치료 방법.A method for treating a blood circulation related disease, comprising administering the composition of any one of claims 1 to 9 to an individual in need thereof.
- 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는, 혈액순환 관련 질환의 예방 또는 개선용 의약외품 조성물.A quasi-drug composition for prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는, 혈액순환 관련 질환의 예방 또는 개선용 사료첨가제.Feed additives for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- 오미자를 함유하는 복합 추출물을 유효성분으로 포함하는 혈액순환 관련 질환의 예방 또는 개선용 건강기능식품 조성물.Health functional food composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
- 제13항에 있어서, 상기 건강기능식품 조성물은 식품학적으로 허용 가능한 담체를 추가적으로 포함하는 것인, 조성물.The composition of claim 13, wherein the nutraceutical composition further comprises a food acceptable carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160127754A KR101988579B1 (en) | 2016-10-04 | 2016-10-04 | A composition containing complex extracts comprising Schisandra chinesis for preventing or treating blood circulation-related diseases |
| KR10-2016-0127754 | 2016-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018066956A1 true WO2018066956A1 (en) | 2018-04-12 |
Family
ID=61831088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2017/011049 WO2018066956A1 (en) | 2016-10-04 | 2017-09-29 | Composition comprising schisandrae fructus-containing composite extract for preventing or treating blood circulation-related disease |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101988579B1 (en) |
| WO (1) | WO2018066956A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102471548B1 (en) * | 2020-07-02 | 2022-11-30 | 한두레축산 영농조합법인 | Schisandra chinesis feed composition, manufacturing method thereof and method for breeding korean native cattle using the same |
| KR102365311B1 (en) * | 2021-11-12 | 2022-02-23 | 이하양 | Feed composition for aged pets comprising herbal extracts and manufacturing method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040057278A (en) * | 2002-12-26 | 2004-07-02 | 한국식품개발연구원 | Composition for prevention and remedy of cardiovascular disease with the extract of schizandrae fructus |
| KR20060007105A (en) * | 2004-07-19 | 2006-01-24 | 이동웅 | A pharmaceutical composition having effects of cure and prevention of obesity and hyperlipidemia by containing konjac and extract of medicinal herbs |
| KR20070111623A (en) * | 2006-05-18 | 2007-11-22 | 동아대학교 산학협력단 | Pharmaceutical composition for treating or preventing diabetic complication containing an extract of chinese herb as an effective ingredient |
| KR101387685B1 (en) * | 2012-09-24 | 2014-04-21 | 이철우 | Pharmaceutical composition comprising the extract of schizandra chinensis as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
| KR20160013410A (en) * | 2014-07-25 | 2016-02-04 | 동의대학교 산학협력단 | prevent or improvement COMPOSITION INCLUDING Schisandra chinensis semen Extracts For vascular disease And Manufacturing Method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329516B (en) * | 2000-12-12 | 2010-09-01 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity |
| KR20150026695A (en) * | 2013-08-30 | 2015-03-11 | 한국 한의학 연구원 | Compositions for treatment and prevention of thrombosis comprising alcohol extract of mulberry leaves as active Ingredient |
-
2016
- 2016-10-04 KR KR1020160127754A patent/KR101988579B1/en active IP Right Grant
-
2017
- 2017-09-29 WO PCT/KR2017/011049 patent/WO2018066956A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040057278A (en) * | 2002-12-26 | 2004-07-02 | 한국식품개발연구원 | Composition for prevention and remedy of cardiovascular disease with the extract of schizandrae fructus |
| KR20060007105A (en) * | 2004-07-19 | 2006-01-24 | 이동웅 | A pharmaceutical composition having effects of cure and prevention of obesity and hyperlipidemia by containing konjac and extract of medicinal herbs |
| KR20070111623A (en) * | 2006-05-18 | 2007-11-22 | 동아대학교 산학협력단 | Pharmaceutical composition for treating or preventing diabetic complication containing an extract of chinese herb as an effective ingredient |
| KR101387685B1 (en) * | 2012-09-24 | 2014-04-21 | 이철우 | Pharmaceutical composition comprising the extract of schizandra chinensis as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
| KR20160013410A (en) * | 2014-07-25 | 2016-02-04 | 동의대학교 산학협력단 | prevent or improvement COMPOSITION INCLUDING Schisandra chinensis semen Extracts For vascular disease And Manufacturing Method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180037642A (en) | 2018-04-13 |
| KR101988579B1 (en) | 2019-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170132705A (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| RU2350120C1 (en) | Nutrition additive and foodstuff containing potato painted in purple colour for patients, suffering from adiposity (versions) | |
| WO2015030293A1 (en) | Composition containing composite extract of grape and schisandra chinensis for preventing or treating metabolic syndrome-related diseases | |
| KR100919852B1 (en) | A composition for the prevention and treatment of edema or dermatitis containing Glehnia littoralis Fr. Schmidt et Miquel extract as an active ingredient | |
| WO2018066956A1 (en) | Composition comprising schisandrae fructus-containing composite extract for preventing or treating blood circulation-related disease | |
| JP7385325B2 (en) | Composition for improving locomotive syndrome | |
| KR20210052377A (en) | Composition for the prevention or treatment of prostate-related disease comprising Rhodiola sachalinensis root extract containing kaempferol and epicatechin gallate | |
| KR101277266B1 (en) | A composition comprising of a sprout extract of Triticum aestivum for treating and preventing obesity disease | |
| KR102696677B1 (en) | A composition for improving, preventing and treating of obesity metabolic disease comprising Rosa multiflora root extract | |
| KR20200140749A (en) | Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata | |
| KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR20200022930A (en) | Use of Arctium lappa extract for eye health | |
| WO2018008999A1 (en) | Composition comprising aster koraiensis extract or fraction thereof as active ingredient for regulating blood glucose and preventing or treating diabetes | |
| JP2019073476A (en) | Agent for atp production promotion | |
| KR102122408B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising roasted Glycyrrhiza uralensis extract as effective component | |
| KR101516764B1 (en) | A composition containing Humulus japonicus extracts for preventing or treating liver disease or atherosclerosis | |
| KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
| KR101793145B1 (en) | A composition for preventing or treating metabolic disease comprising Sicyos angulatus extract or fraction thereof | |
| KR101166852B1 (en) | Compositions comprising Hippophae rhamnoides L. leaves or extracts thereof for amelioration of body lipid | |
| KR100760386B1 (en) | Composition comprising the extract of ACP mixed crude drugs for preventing and treating arthritis | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR102157413B1 (en) | Composition for preventing and treating liver diseases comprising extract of sargassum serratifolium | |
| KR20140083493A (en) | Composition for anti-obesity comprising extract of Sargassum fulvellum or Sargassum horneri as an effective component | |
| WO2023224305A1 (en) | Composition for preventing, ameliorating, or treating arthritis and joint pain comprising lysimachia mauritiana extract as active ingredient | |
| KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17858750 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17858750 Country of ref document: EP Kind code of ref document: A1 |